IL189201A

Substituted n-((phenylamino)phenyl)-sulfonamides, pharmaceutical compositions containing the same and uses of the same

Abstract

This record has no abstract on file.

IL189201A, drawing sheet 1 — Sheet 1 of 128

Term

No projected expiry on record.

1 claim: 1 independent, 0 dependent

1
CLAIMS:1. A compound of formula I where G is Ria, Rib, Ric, Rid, or Rie,;R° is H, halogen, CH3NH-, (CH3)2N-, C1-C6 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl, C2-Ce alkenyl, C2-C6 alkynyl, said alkyl, alkoxy, cycloalkyl, alkenyl, and alkynyl groups optionally substituted with 1-3 substituents selected independently from halogen, OH, CN, cyanomethyl, nitro, phenyl, and trifluoromethyl, and said C1-C6 alkyl and C1-C4 alkoxy groups also optionally substituted with OCH3 or OCH2CH3;X is F, Cl, or methyl;Y is I, Br, Cl, CF3, Ci-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, cyclopropyl, phenyl, pyridyl, pyrazolyl, OMe, OEt, or SMe, where all said methyl, ethyl, C1-C3 alkyl, and cyclopropyl groups of X and Y are optionally substituted with OH, where all said phenyl, pyridyl, pyrazolyl groups of Y are optionally substituted with halogen, acetyl, methyl, and trifluoromethyl, and where all said methyl groups of X and Y are optionally substituted with one, two, or three F atoms;and Z is H or F;where Ria is methyl, optionally substituted with 1-3 fluorine atoms or 1-3 chlorine atoms, or with OH, cyclopropoxy, or Ci- C4 alkoxy, where said cyclopropoxy group or the Ci- C3 alkyl moieties of said Ci- C3 alkoxy groups are optionally substituted with one hydroxy or methoxy group, and where all C3- alkyl groups within said Cp C4 alkoxy are optionally further substituted with a second OH group;Rib is CH(CH3)-Ci-3 alkyl or C3-C6 cycloalkyl, said alkyl and cycloalkyl groups optionally substituted with 1-3 substituents selected independently from F, Cl, Br, I, OH, OCH3, and CN;112 189201/2 Ric is (CH2)nOmR', where m is 0 or 1;where, when m is 1, n is 2 or 3, and when m is 0, n is 1 or 2;and where R' is Ci-Cg alkyl, optionally substituted with 1-3 substituents selected independently from F, Cl, OH, OCH3, OCH2CH3, and C3-C6 cycloalkyl;Rid is C(A)(A')(B)- where B, A, and A' are, independently, H or Cm alkyl, optionally substituted with one or two OH groups, or A and A', together with the carbon atom to which they are attached, form a 3- to 6- member saturated ring;and Rie is benzyl or 2-phenyl ethyl, in which the phenyl group is optionally substituted, as shown below: (CH2)qwhere q is 1 or 2, R2, R3 and R4 are, independently, H, F, Cl, Br, CH3, CH2F, CHF2, CF3, OCH3, OCH2F, OCHF2, OCF3, ethyl, «-propyl, isopropyl, cyclopropyl, isobutyl, sec-butyl, /er/-butyl, and methylsulfonyl, and R4 may also be nitro, acetamido, amidinyl, cyano, carbamoyl, methylcarbamoyl, dimethylcarbamoyl, l,3,4-oxadiazol-2yl, 5-methyl-l,3,4-oxadiazol, 1,3,4-thiadiazol, 5-methyl-l,3,4-thiadiazol lH-tetrazolyl, N-morpholyl carbonyl amino, N-morpholylsulfonyl and N-pyrrolidinylcarbonylamino;

1,474 paragraphs in 236 sections, as filed

This application claims priority to U.S. Provisional Application Ser. No. 60/701,814, filed July 21, 2005; to U.S. Provisional Application Ser. No. 60/706,719, filed August 8, 2005; and to U.S. Provisional Application Ser. No. 60/731,633, filed October 28,2005, both of which are hereby incorporated by reference herein in their entirety.

Field of the Invention

This invention concerns N-(2-arylamino) aryl sulfonamides, which are inhibitors of 15 MEK. Such compounds are useful in the treatment of cancer and other hyperproliferative diseases.

Background of the invention

Oncogenes -- genes that contribute to the production of cancers — are generally mutated forms of certain normal pellular genes (proto-oncogenes). Oncogenes often encode abnormal versions of signal pathway components, such as receptor tyrosine kinases, serine-threonine kinases, or downstream signaling molecules. The central downstream signaling molecules are the Ras proteins, which are anchored on the inner surfaces of cytoplasmic membranes, and which hydrolyze bound guanosine triphosphate (GTP) to guanosine diphosphate (GDP). When activated by a growth factor, growth factor receptors . initiate a chain of reactions that leads to the activation of guanine nucleotide exchange activity on Ras. Ras alternates between an active on state with a bound GTP (hereafter Ras.GTP) and an inactive off1 state with a bound GDP. The active on state, Ras.GTP, binds to and activates proteins that control the growth and differentiation of cells.

For example, in the mitogen-activatedprotein kinase (MAP kinase) cascade, Ras.GTP leads to the activation of a cascade of serine/threonine kinases . One of several groups of kinases known to require a Ras.GTP for their own activation is the Raf family. The

Raf proteins activate MEK1 and MEK2, abbreviations for mitogen-activated FRKactivating Unases (where ERK is extracellular signal-regulated protein kinase, another designation for ΜΑΡΚ). MEK1 and MEK2 are dual-function serine/threonine and tyrosine

WO 2007/014011

PCT/US2006/028326 protein kinases and are also known as MAP kinase kinases. Thus, Ras.GTP activates Raf, which activates MEK1 and MEK2, which activate MAP kinase (MAPK). Activation of MAP kinase by mitogens appears to be essential for proliferation, and constitutive activation of this kinase is sufficient to induce cellular transformation. Blockade of downstream Ras signaling, as by use of a dominant negative Raf-1 protein, can completely inhibit mitogenesis, whether induced from cell surface receptors or from oncogenic Ras mutants.

The interaction of Raf and Ras is a key regulatory step in the control of cell proliferation. To date, no substrates ofMEK other than MAPK have been identified;

however, recent reports indicate that MEK may also be activated by other upstream signal proteins such as MEK kinase or MEKK1 and PKC. Activated MAPK translocates and accumulates in the nucleus, where it can phosphorylate and activate transcription factors such as Elk-1 and Sap la, leading to the enhanced expression of genes such as that for c-fos.

Once activated, Raf and other kinases phosphorylate MEK on two neighboring serine residues, S218 and S222 in the case of MEK-1. These phosphorylations are required for activation ofMEK as a kinase. In turn, MEK phosphorylates MAP kinase on two residues separated by a single amino acid: a tyrosine, Y185 and a threonine, T183. MEK appears to associate strongly with MAP kinase prior to phosphorylating it, suggesting that phosphorylation of MAP kinase by MEK may require a prior strong interaction between the two proteins. Two factors - MEK’s unusual specificity and its requirement for a strong interaction with MAP kinase prior to phosphorylation -- suggest that MEK’s mechanism of action may differ sufficiently from the mechanisms of other protein kinases as to allow for selective inhibitors ofMEK. Possibly, such inhibitors would operate through allosteric mechanisms rather than through the more usual mechanism involving blockage of an ATP binding site.

Thus, MEK1 and MEK2 are validated and accepted targets for anti-proliferative therapies, even when the oncogenic mutation does not affect MEK structure or expression.

See, e.g., U.S. Patent Publications 2003/0149015 by Barrett et al. and 2004/0029898 by Boyle et al.

WO 2007/014011

PCT/US2006/028326

Several examples of l-substituted-2(p-substituted-phenylamino)-aryl inhibitors of MEK have been reported. U.S. Patent Nos. 6,440,966 and 6,750,217 and corresponding publication WO 00/42003 described carboxylic and hydroxamic acid esters and N-substituted amide derivatives of sulfonamide-substituted-2(4-iodophenylamino)-benzoic acid esters and

N-substituted benzamides as functioning as MEK inhibitors. The sulfonamide may also be N-substituted.

U.S. Patent 6,545,030 and corresponding publication WO 00/42029 describe MEK inhibitors that are l-heterocyclyl-2(4-iodophenylamino)-benzene, where the heterocycle is a five-membered nitrogen-containing ring such as pyrazole, triazole, oxazole, isoxazole, and isoxazolinone. The more recent U.S. Patent Publication 2005/004186 describes related compounds in which the 4-iodo substituent of the ‘030 patent is replaced by a very broad genus of moieties including alkyl, alkoxy, acyloxy, alkenyl, carbamoyl, carbamoylalkyl, carboxyl, carboxylalkyl, N-acylsulfonamido, and others.

U.S. Patent 6,469,004 and corresponding publication WO 00/42022 describe carboxylic and hydroxamic acid esters of a group of heterocyclo-condensed phenylene compounds, i.e., benzimidazoles, benzooxazoles, benzothiazoles, benzothiadiazoles, quinazolines, etc.. The heterocycles are 7-F-6-(4-iodo-phenylamino)-5-carboxylic acid esters, carboxylic acid amides or hydroxamic acid esters. More recent publication U.S.

2005/0026970 described similar compounds in which the 4-iodo substituent was replaced by a very broad genus of structures. Related compounds are described in patent publications WO 03/077855, WO 03/77914 and US 2005/0554701. Further examples of 2-(4iodophenylamino)-phenylhydroxamic acid esters which are reported to be useful as MEK inhibitors can be found in WO 2005/028426.

Patent Publication WO 02/06213 and corresponding U.S. Application Ser. No. 10/333,399 (U.S. 2004/0054172) describe hydroxy-substituted acid esters of 1-oxamic acid2(4-halophenylamino)-3,4-difluorobenzene. U.S. Patent No. 6,891,066 and corresponding publication WO 03/62191 describe similar compounds wherein the 4-halo substituent is replaced by a very broad genus of structures. Among the substituents in the 4-position were methyl, ethyl, ethynyl, and 2-hydroxyethyl. Specific related compounds are described in U.S. Patent No. 6,770,778. .

WO 2007/014011

PCT/US2006/028326

Patent Publication WO 04/083167, published September 30, 2004, (in Japanese) discloses more than two thousand - but provides NMR data for only 400 - l-(N-substituted sulfonyl urea)-2(2,4-dihalophenylamino)-3,4-difluorobenzenes and asserts that they useful as MEK inhibitors. Data indicating inhibition of MEK were presented for a subgroup of just twelve. In addition to a secondary or tertiary amine, these twelve compounds all contained one of the following groups: an N, N-disubstituted sulfonyl urea, N-piperazinesulfonamide, N-piperidinesulfonamide or N-pyrrolidinesulfonamide.

The MEK cascade has also been implicated in inflammatory diseases and disorders. U.S. Application Publication No. 2006/0030610 to Koch et al., U.S. Application Publication

No. 2006/0140872 to Furue et al. This includes both acute and chronic inflammation disorders. Examples of such disorders are allergic contact dermatitis, rheumatoid arthritis, osteoarthritis, inflammatory bowel diseases, chronic obstructive pulmonary disorder, psoriasis, multiple sclerosis, asthma, diseases and disorders related to diabetic complications, and inflammatory complications of the cardiovascular system such as acute coronary syndrome. Among inflammatory bowel diseases are Crohn's disease and ulcerative colitis.

All cited references are incorporated herein by reference.

Brief Description of the Invention

This invention provides compounds of formula I

I where G is Ria, Rib, R|C, Rid, Rie, Αη, Ar2or Ar3; R° is H, halogen, C]-C6 alkyl, C,-C4 alkoxy, C3-C6 cycioalkyl, C2-C6 alkenyl, C2-C6 alkynyi, said alkyl, cycloalkyl, alkenyl, and alkynyl groups optionally substituted with 1-3 substituents selected independently from halogen, OH, CN, cyanomethyl, nitro, phenyl, and trifluoromethyl, and said C1-C6 alkyl and C1-C4 alkoxy groups also optionally substituted with OCH3 or OCH2CH3; X is F, Cl or

WO 2007/014011

PCT/US2006/028326 methyl; Y is I, Br, Cl, CF3, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, cyclopropyl, phenyl, pyridyl, pyrazolyl, OMe, OEt, or SMe, where all said methyl, ethyl, C1-C3 alkyl, and cyclopropyl groups of X and Y are optionally substituted with OH, all said phenyl, pyridyl, pyrazolyl groups of Y are optionally substituted with halogen, acetyl, methyl, and trifluoromethyl, and all said methyl groups of X and Y are optionally substituted with one, two, or three F atoms; and Z is H or F, where Ria is methyl, optionally substituted with 1-3 fluorine atoms or 1-3 chlorine atoms, or with OH, cyclopropoxy, or Cj- C4 alkoxy, where the Cr C4 alkyl moieties of said Cr C4 alkoxy groups are optionally substituted with one hydroxy or methoxy group, and where all C2- C4 alkyl groups within said Cr C4 alkoxy are optionally further substituted with a second OH group;

Rib is CH(CH3)-Ci.3 alkyl or C3-C6 cycloalkyl, said methyl, alkyl, and cycloalkyl groups optionally substituted with 1-3 substituents selected independently from F, Cl, Br, I, OH, Cr C4 alkoxy, and CN;

Ric is (CH2)nOmR', where m is 0 or 1; where, when m is 1, n is 2 or 3, and when m is 0, n is 1 or 2; and where R’ is Ci-C6 alkyl, optionally substituted with 1-3 substituents selected independently from F, Cl, OH, OCH3, OCH2CH3, and C3-C6 cycloalkyl;

Rid is C(A)(A j(B)- where B, A, and A' are, independently, H or Ομ alkyl, optionally substituted with one or two OH groups or halogen atoms, or A and A', together with the carbon atom to which they are attached, form a 3- to 6- member saturated ring, said ring optionally containing one or two heteroatoms selected, independently, from Ο, N, and S and optionally substituted with one or two groups selected independently from methyl, ethyl, and halo;

Rie is benzyl or 2-phenyl ethyl, in which the phenyl group is optionally substituted

WO 2007/014011

PCT/US2006/028326 where q is 1 or 2, R2, R3 and R4 are, independently, H, F, Cl, Br, CH3, CH2F, CHF2, CF3, OCH3, OCH2F, OCHF2, OCF3, ethyl, «-propyl, isopropyl, cyclopropyl, isobutyl, scc-butyl, tert-butyl, and methylsulfonyl, and R4 may also be nitro, acetamido, amidinyl, cyano, carbamoyl, methylcarbamoyl, dimethylcarbamoyl, l,3,4-oxadiazol-2-yl, 5-methyl-l,3,45 oxadiazolyl, 1,3,4-thiadiazolyl, 5-methyl-l,3,4-thiadiazol-777-tetrazolyl, N-morpholinyl carbonylamino, N-morpholinylsulfonyl, and N-pyrrolidinylcarbonylamino; R5 and R6 are, independently, H, F, Cl, or methyl;

Ari is

where U and V are, independently, N, CR2 or CR3; R2, R3 and R4 are, independently, H, F, Cl, Br, CH3, CH2F, CHF2! CF3, OCH3, OCH2F, OCHF2, OCF3, ethyl, «-propyl, isopropyl, cyclopropyl, isobutyl, sec-butyl, tert-butyl, and methylsulfonyl, and R4 may also be nitro, acetamido, amidinyl, cyano, carbamoyl, methylcarbamoyl, dimethylcarbamoyl, 1,3,4oxadiazol-2-yl, 5-methyl-l,3,4-oxadiazol, 1,3,4-thiadiazol, 5-methyl-l,3,4-thiadiazol 1Htetrazolyl, N-morpholinylcarbonylamino, N-morpholinylsulfonyl and Npyrrolidinylcarbonylamino; R5 and Re are, independently, H, F, Cl or methyl;

Ar2 is

Ar2 where the dashed line represents a double bond which may be located formally either between V and the carbon between U and V, or between U and the carbon between U and V;

where U is -S-, -O- or -N = and where, when U is -O- or -S-, V is -CH=, -CC1= or -N =; and when U is -N =, V CH=, or -NCH3-; R7 and Rg are, independently, H, methoxycarbonyl, methylcarbamoyl, acetamido, acetyl, methyl, ethyl, trifluoromethyl, or halogen.

Ar3 is

WO 2007/014011

PCTYUS2006/028326

R7

r8

Ar3 where U is -NH-, -NCH3- or -O-; and R7 and Rg are, independently, H, F, Cl, or methyl.

Such compounds are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.

This invention is also directed to pharmaceutical compositions comprising pharmaceutically effective amounts of a compound of formula I or a pharmaceutically acceptable salt, ester, prodrug, solvate, or hydrate thereof, and a pharmaceutically acceptable carrier. Such compositions may contain adjuvants, excipients, preservatives, agents for delaying absorption, fillers, binders, adsorbents, buffers, disintegrating agents, solubilizing agents, other carriers, and other inert ingredients. Methods of formulation of such compositions are well-known in the art.

The invention is also directed to a method of treating a hyperproliferative disorder in a mammal, including a human, comprising administering to said mammal a therapeutically effective amount of the compound of formula 1, or a pharmaceutically acceptable salt, salt, ester, prodrug or hydrate thereof.

This invention is also directed to a method of treating an inflammatory disease, condition, or disorder in a mammal, including a human, comprising administering to said mammal a therapeutically effective amount of the compound of formula I, or a pharmaceutically acceptable salt, salt, ester, prodrug or hydrate thereof.

The invention is also directed to a method of treating a disorder or condition which is modulated by the MEK cascade in a mammal, including a human, comprising administering to said mammal a therapeutically effective amount of the compound of formula I, or a pharmaceutically acceptable salt, salt, ester, prodrug or hydrate thereof.

The appropriate dosage for a particular patient can be determined, according to known methods, by those skilled in the art.

WO 2007/014011

PCT/US2006/028326

In one subgeneric embodiment, this invention provides a compound of formula IA-1,

where R)a is defined as above.

In another embodiment the invention provides a compound of formula IA-2, where Ru is defined as above and where R°' is R°, defined above, other than H.

In another embodiment, the invention provides a compound of formula IB-1,

where X and Y are defined as for formula I, and where R,b is defined as above for formula I.

In another embodiment, the invention provides a compound of formula IB-2,

WO 2007/014011

PCT/US2006/028326

where Rib is defined as above for formula I, and where R°' is R°, defined above, other than H.

In a third embodiment, this invention provides a compound of formula IC-1,

where R]C is (CH2)nOmR'5 where m is 0 or 1, n is 2 or 3 when m is 1, and n is 1 or 2 when m is 0, and R' is C1-C6 alkyl, optionally substituted with 1-3 substituents selected independently from F, Cl, OH, OCH3, OCH2CH3, and C3-C6 cycloalkyl.

In another embodiment, this invention provides a compound of formula IC-2,

where Rjc is defined as above and where R°' is R°, defined above, other than H.

In another embodiment, this invention provides a compound of formula ID-1

WO 2007/014011

PCT/US2006/028326

F

ID-1 where Rid is C(A)(A')(B)- where B, A, and A' are, independently, H or Cm alkyl, optionally substituted with one or two OH groups or halogen atoms, or A and A’, together with the carbon atom to which they are attached, form a 3- to 6- member saturated ring, said ring optionally containing one or two heteroatoms selected, independently, from Ο, N, and S and optionally substituted with one or two groups selected independently from methyl, ethyl, and halo

In another embodiment, the invention provides a compound of formula ID-2,

NH

ID-2 where Rid is defined as above and where R°' is R°, defined above, other than H.

In another embodiment, this invention provides a compound of formula IE-1.

IE-1 where Rie is defined as above.

In another embodiment, this invention provides a compound of formula IE-2,

WO 2007/014011

PCT/US2006/028326

where R°' is R°, defined above, other than H.

In another embodiment, this invention provides a compound of formula II-A, where G is Ari,

where R2.6, U, and V are defined as above.

In another embodiment, this invention provides a compound of formula Π-Β,

where R°' is R°, defined above, other than H.

WO 2007/014011

PCT/US2006/028326

In another embodiment, this invention provides a compound of formula III-A

In another embodiment, this invention provides a compound of formula III-B

where R°' is R°, defined above, other than H.

In additional subgeneric embodiments, this invention provides compounds of formulas IA-1, IA-2, IB-1, IB-2, IC-1, IC-2, ID-1, ID2, Π-A, II-B, 1H-A, and ΠΙ-B, where X is F, Cl, or CH3: Y is I, Br, Cl, CF3, or Ci-C3 alkyl, and Z is H or F.

In additional subgeneric embodiments, this invention provides compounds of formulas IA-2, IB-2, IC-2, ID-2, II-B, and III-B, where X is F, Cl, or CH3: Y is I, Br, Cl, CF3, or Ci-C3 alkyl, Z is H or F, and R° is halogen, C|-C6 alkyl, monohalo Ci-Cg alkyl, C3-Cg cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, phenyl, monosubstituted phenyl, OR3,0-C(=O)R4, or C(=O)OR5.

In additional subgeneric embodiments, this invention provides or contemplates compounds of formulas IA-2, IB-2, IC-2, ID-2, Π-B, and IH-B, where X is F, Cl, or CH3: Y is

WO 2007/014011

PCT/US2006/028326

I, Br, Cl, CF3, or C1-C3 alkyl, Z is H or F, and R° is furyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, or pyrazolyl.

In additional subgeneric embodiments, this invention provides compounds of formulas IA-2, IB-2, IC-2, ID-2, II-B, and III-B, where X is F, Cl, or CH3: Y is I, Br, Cl, CF3, or C1-C3 alkyl, Z is H or F, and R° is F, Cl, C]-C4 alkyl, C1-C3 alkoxy, trifluoromethoxy, or 2methoxy-ethoxy.

In a more specific subgeneric embodiment, this invention provides a compound of formula IA-1, where R]a is methyl, monohalomethyl, C1-C3 alkoxymethyl, or cyclopropoxymethyl.

In another more specific subgeneric embodiment, this invention provides a compound of formula IA-2, where R]a is methyl, monohalomethyl, C1-C3 alkoxymethyl, or cyclopropoxy methyl and where R°' is F, Cl, C1-C3 alkyl, monochloro C1-C3 alkyl, C1-C3 alkoxy, trifluoro methoxy, or 2-methoxy-ethoxy,

In a more specific subgeneric embodiment of formula IB-1, this invention provides a compound of formula IB-1, where Rib is isopropyl, 2-butyl, 2-pentyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, all optionally substituted with 1 or 2 substituents selected independently from F, Cl, OH, and OCH3; Y is Br, I, methyl, or trifluoromethyl.

In a more specific subgeneric embodiment of formula IB-2, this invention provides a compound of formula IB-2, where Rlb is isopropyl, 2-butyl, 2-pentyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, optionally substituted with 1 or 2 substituents selected independently from F, Cl, OH, and OCH3; Y is Br, I, methyl, or trifluoromethyl; and R°' is F, Cl, C1-C3 alkyl, monochloro C1-C3 alkyl, C1-C3 alkoxy, trifluoromethoxy, or 2-methoxyethoxy.

In a still more specific subgeneric embodiment of formula IB-1, this invention provides a compound of formula IB-1, where Rib is isopropyl, 2-butyl, 2-pentyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, all optionally substituted with one CI, with one or with 1 or 2 OH groups; and Y is Br, I, methyl, or trifluoromethyl.

In a more specific subgeneric embodiment of formula IB-2, this invention provides a compound of formula IB-2, where R]b is isopropyl, 2-butyl, 2-pentyl, cyclopropyl,

WO 2007/014011

PCT/US2006/028326 cyclobutyl, cyclopentyl, or cyclobexyl, all optionally substituted with one Cl or with 1 or 2 OH groups; Y is Br, I, methyl, or trifluoromethyl; and R°' is F, Cl, Ci-C3 alkyl, monochloro C1-C3 alkyl, CrC3 alkoxy, trlfluoromethoxy, or 2-methoxy-ethoxy.

In another more specific subgeneric embodiment, this invention provides a compound of formula IC-1 or IC-2, where m is zero, n is 1 or 2, and R' is C1-C4 alkyl, optionally substituted as described above.

In another more specific subgeneric embodiment, this invention provides a compound of formula IC-1 or IC-2, where m is 1, n is 2 or 3, and R' is C1-C4 alkyl, optionally substituted as described above.

In a still more specific subgeneric embodiment, this invention provides a compound of formula IC-1 or IC-2, where m is zero, n is 1 or 2, and R' is C1-C4 alkyl, optionally substituted with 1 -3 groups selected from OH, OCH3, Cl, and cyclopropyl.

In another more specific subgeneric embodiment, this invention provides a compound of formula ID-1, where Rld is cycloalkyl or l-alkyl-cycloallcyl, in which the l-alkyl group is optionally substituted with one or two OH groups or with one or two halogen atoms.

In another more specific subgeneric embodiment, this invention provides a compound of formula ID-2, where R°' is halogen, C]-C6 alkyl, monohalo Ci-C6 alkyl, Ο3-Οβ cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, phenyl, monosubstituted phenyl, OR3,0-C(=O)R4, or C(=O)OR5; and Rid is cycloalkyl or 1-alkyl-cycloalkyl, in which the l-alkyl group is optionally substituted with one or two OH groups or with one or two halogen atoms.

In another more specific subgeneric embodiment, this invention provides a compound of formula ID-2, where R°' is furyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, or pyrazolyl; and Rid is cycloalkyl or 1-alkyl-cycloalkyl, in which the l-alkyl group is optionally substituted with one or two OH groups or one or two halogen atoms.

In another more specific subgeneric embodiment, this invention provides a compound of formula ID-1, where Rid is cycloalkyl or 1 -alkyl-cycloalkyl, in which the l-alkyl group is optionally substituted with one or two OH groups, and where Y is Br, I, methyl, or trifluoromethyl.

WO 2007/014011

PCT/US2006/028326

In another more specific subgeneric embodiment, this invention provides a compound of formula ID-1, where Rid is cycloalkyl or 1-alley 1-cycloalkyl, in which the 1-alkyl group is optionally substituted with one or two fluorine or chlorine atoms, and where Y is Br, I, methyl, or trifluoromethyl.

In another more specific subgeneric embodiment, this invention provides a compound of formula ID-2, where Rid is cycloalkyl or (1-alkyl)-cycloalkyl, in which the 1-alkyl group is optionally substituted with one or two OH groups, and where R°' is F, Cl, C1-C3 alley 1, monochloro C1-C3 alkyl, C1-C3 alkoxy, trifluoromethoxy, or 2-methoxy-ethoxy.

In another more specific subgeneric embodiment, this invention provides a compound of formula ID-1, where is tetrahydrofuryl, tetrahydrothienyl, pyrrolidyl, piperidyl, piperazinyl, or morpholyl, each optionally substituted as described above, and where Y is Br, I, methyl, or trifluoromethyl.

In another more specific subgeneric embodiment, this invention provides a compound of formula ID-1, where Rid is oxazolidinyl, thiazolidinyl, isoxazolidinyl, isothiazolidinyl, tetrahydrofuryl, tetrahydrothienyl, pyrrolidyl, piperidyl, piperazinyl, or morpholyl, each optionally substituted as described above, and where Y is Br, I, methyl, or trifluoromethyl.

In another more specific subgeneric embodiment, this invention provides a compound of formula ID-2, where Rid is cyclopropyl or 1-alkyl-cyclopropyl, in which the 1-alkyl group is optionally substituted with one or two OH groups, and where R°' is F, Ci, methyl, ethyl, chloromethyl, C1-C2 alkoxy, trifluoromethoxy, or 2-methoxy-ethoxy.

In an even more specific embodiment, the invention provides a compound of formula ID-1 in which Ru is l-(monohydroxyalkyl) cycloalkyl.

In another more specific embodiment, the invention provides a compound of formula ED-2 in which Rid is l-(monohydroxyalkyl) cycloalkyl, where R°' is F, Cl, methyl, ethyl, chloromethyl, C1-C2 alkoxy, trifluoromethoxy, or 2-methoxy-ethoxy.

In an even more specific embodiment, the invention provides a compound of formula ID-1 in which Rid is 1 -(dihydroxyalkyl) cycloalkyl.

WO 2007/014011

PCT/US2006/028326

In another more specific embodiment, the invention provides a compound of formula ID-2 in which R]d is 1-(dihydroxy alkyl) cycloalkyl, where R°' is F, Cl, methyl, ethyl, chloromethyl, C1-C2 alkoxy, trifluoromethoxy, or 2-methoxy-ethoxy.

In a more specific subgeneric embodiment of formula IIA, this invention provides a compound of formula Π-Al, which is a compound of formula II-A, in which U is CR2 and V is N.

In another more specific, subgeneric embodiment, this invention provides a compound of formula IIB-1, which is a compound of formula II-B, in which U in which U and V are both N.

In a more specific, subgeneric embodiment, this invention provides a compound of formula IIA-3, which is a compound of formula HA in which U is CR2 and V is CR3.

WO 2007/014011

PCT/US2006/028326

In a still more specific subgeneric embodiment, this invention provides a compound 5 of formula I, where G is An and Ari is phenyl or monosubstituted phenyl, R° is F, methyl, ethyl, C,-C3 alkoxy, trifluoromethoxy, or 2-methoxy-ethoxy; X is F, Cl, or CH3; Y is I; and Z is F.

In another subgeneric embodiment, this invention provides a compound of formula I, where G is An, where An is phenyl or monosubstituted phenyl, R° is halogen, C1-C6 alkyl,

C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, all such alkyl, cycloalkyl, alkenyl, and alkynyl groups optionally substituted with 1-3 substituents selected independently from halogen, OH, CN, cyanomethyl, nitro, phenyl, and trifluoromethyl; or R° is phenyl, OR3, furyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, or pyrazolyl.

In a more specific subgeneric embodiment, this invention provides a compound of formula I, where A is An, where An is phenyl or monosubstituted phenyl, R° is F, Cl, Ci-C3 alkyl, Ci-C3 alkoxy, 2-methoxyethoxy, C2-C3 alkenyl, C2-C3 alkynyl, trifluoromethyl, phenyl, furyl, or thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, or pyrazolyl; X is F,

Cl, or methyl; Y is I, Br, Cl, CF3, or Ci-C3 alkyl; and Z is F.

In another still more specific subgeneric embodiment, this invention provides G compound of formula I, where G is An, where An is phenyl or monosubstituted phenyl, R° is Η; X is F, Cl, or CH3; Y is Br or I; and Z is F.

In another subgeneric embodiment his invention provides G compound of formula I, where G is Ar2, where Ar2 is 2-thienyl, 2-furyl, 3-thienyl, 3-furyl, 2-pyrrolyl, or 3-pyrroiyl,

WO 2007/014011

PCT/US2006/028326 all optionally substituted with methoxycarbonyl, methylcarbamoyl, acetamido, acetyl, methyl, ethyl, trifluoromethyl, or halogen.

In a more specific subgeneric embodiment his invention provides G compound of formula I, where G is Ar2, where Ar2 is 2-thienyl, 2-furyl, 3-thienyl, 3-furyl, 2-pyrrolyl, or 3pyrrolyl, all optionally substituted with methoxycarbonyl, methylcarbamoyl, acetamido, acetyl, methyl, ethyl, trifluoromethyl, or halogen; R° is other than Η; X is F, Cl, or CH3: Y is I, Br, Cl, CF3, or C1-C3 alkyl, and Z is H or F.

In another subgeneric embodiment his invention provides G compound of formula I, where G is Ar2, where Ar2 is 2-thienyl, 2-furyl, 3-thienyl, 3-furyl, 2-pyrrolyl, or 3-pyrroIyI, all optionally substituted with methoxycarbonyl, methylcarbamoyl, acetamido, acetyl, methyl, ethyl, trifluoromethyl, or halogen; R° is F, Cl, C1-C3 alkyl, monochloro C1-C3 alkyl, C1-C3 alkoxy, trifluoromethoxy, methyloxy-methoxy, or 2-methoxy-ethoxy; X is F, Cl, or CH3: Y is I, Br, Cl, CF3, or C1-C3 alkyl, and Z is H or F.

In another subgeneric embodiment his invention provides G compound of formula I, where G is Ar2, where Ar2 is 2-thienyl, 2-furyl, 3-thienyl, 3-furyl, 2-pyrrolyl, or 3-pyrrolyl, all optionally substituted with methoxycarbonyl, methylcarbamoyl, acetamido, acetyl, methyl, ethyl, trifluoromethyl, or halogen; R° is Η; X is F, Cl, or CH3: Y is I, Br, Cl, CF3, or C1-C3 alkyl, and Z is H or F.

In another subgeneric embodiment his invention provides G compound of formula I, where G is Ar2, where Ar2 is thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, or pyrazolyl, all optionally substituted with methoxycarbonyl, methylcarbamoyl, acetamido, acetyl, methyl, ethyl, trifluoromethyl, or halogen; R° is H or methoxy; X is F, CI, or CH3: Y is I, Br, Cl, CF3, or C1-C3 alkyl, and Z is H or F.

WO 2007/014011

PCT/US2006/028326

Detailed description of the invention

As used herein a pharmaceutically acceptable salt includes salts that retain the biological effectiveness of the free acids and bases of the specified compound and that are not biologically or otherwise undesirable. A compound of this invention may possess acidic or basic groups and therefore may react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. Examples of pharmaceutically acceptable salts include those salts prepared by reaction of the compounds of this invention with a mineral or organic acid or an inorganic base, such salts including sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyn-l,4-dioates, hexyne-l,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, .γ-hydroxybutyrates, giycollates, tartrates, methanesulfonates, propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, and mandelates.

As used herein, a “prodrug is a compound that may be converted under physiological conditions or by solvolysis to the specified compound or to a pharmaceutically acceptable salt of such compound. Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more amino acid residues, is covalently joined through an amide or ester bond to a free amino, hydroxy, or carboxylic acid group of compounds of Formulas I.

The amino acid residues contemplated include but are not limited to the 20 naturallyoccurring amino acids. Other suitable amino acids include 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methyl histidine, norvaline, β-alanine, γ-aminobutyric acid, cirtulline, homocysteine, homoserine, ornithine and methionine sulfone. Additional types of prodrugs are well known in the art.

The tables below show the individual compounds provided or contemplated by this invention.

Table I shows embodiments of this invention which are compounds of formula IA-1.

WO 2007/014011

PCT/US2006/028326

Table 1: Embodiments According to Formula IA-1

WO 2007/014011

PCT/US2006/028326

<td> CHClz</td><td> F</td><td> I</td><td> F</td>

<td> CHClz</td><td> Cl</td><td> I</td><td> F</td>

<td> CHClz</td><td> F</td><td> Br</td><td> F</td>

<td> CHClz</td><td> Cl</td><td> Br</td><td> F</td>

<td> CHClz</td><td> F</td><td> ch3</td><td> F</td>

<td> CHClz</td><td> Cl</td><td> ch3</td><td> F</td>

<td> CHClz</td><td> F</td><td> cf3</td><td> F</td>

<td> CHzOH</td><td> F</td><td> I</td><td> F</td>

<td> CHzOH</td><td> F</td><td> Br</td><td> F</td>

<td> CHzOH</td><td> Cl</td><td> Br</td><td> F</td>

<td> CHzOH</td><td> Cl</td><td> ch3</td><td> F</td>

<td> CHzOH</td><td> F</td><td> cf3</td><td> F</td>

<td> CHzOH</td><td> Cl</td><td> cf3</td><td> F</td>

<td> CHzOMe</td><td> F</td><td> I</td><td> F</td>

<td> CHzOMe</td><td> Cl</td><td> I</td><td> F</td>

<td> CHzOMe</td><td> F</td><td> Br</td><td> F</td>

<td> CHzOMe</td><td> Cl</td><td> Br</td><td> F</td>

<td> CHzOMe</td><td> F</td><td> ch3</td><td> F</td>

<td> CHzOMe</td><td> F</td><td> cf3</td><td> F</td>

<td> CHzOMe</td><td> Cl</td><td> cf3</td><td> F</td>

<td> CHzOMe</td><td> F</td><td> CsCH</td><td> F</td>

<td> CHzOMe</td><td> Cl</td><td> SCH3</td><td> F</td>

WO 2007/014011

PCT/US2006/028326

WO 2007/014011

PCT/US2006/028326

Table 2: Embodiments According to Formula IB

WO 2007/014011

PCT/US2006/028326

<td> ></td><td> F</td><td> CHZOH</td><td> F</td>

WO 2007/014011

PCT/US2006/028326

WO 2007/014011

PCT/US2006/028326

<td> ApCHa O’</td><td> Cl</td><td> CF3</td><td> F</td>

Table 3 shows embodiments according to formula IC

Table 3 Embodiments According to Formula IC

WO 2007/014011

PCT/US2006/028326

<td> n-butyl</td><td> F</td><td> I</td><td> F</td>

<td> n-butyl</td><td> Cl</td><td> I</td><td> F</td>

<td> n-butyi</td><td> F</td><td> Br</td><td> F</td>

<td> n-butyl</td><td> Cl</td><td> Br</td><td> F</td>

<td> n-butyl</td><td> F</td><td> ch3</td><td> F</td>

<td> n-butyl</td><td> Cl</td><td> ch3</td><td> F</td>

WO 2007/014011

PCT/US2006/028326

<td> «-butyl</td><td> F</td><td> och3</td><td> F</td>

<td> «-butyl</td><td> Cl</td><td> och3</td><td> F</td>

<td> «-butyl</td><td> ch3</td><td> och3</td><td> F</td>

<td> «-butyl</td><td> Cl</td><td> och2ch3</td><td> F</td>

<td> «-butyl</td><td> F</td><td> och2ch3</td><td> F</td>

<td> «-butyl</td><td> ch3</td><td> och2ch3</td><td> F</td>

<td> «-butyl</td><td> F</td><td> och2ch2oh</td><td> F</td>

<td> «-butyl</td><td> F</td><td> cf3</td><td> F</td>

<td> «-butyl</td><td> Cl</td><td> cf3</td><td> F</td>

<td> .sec-butyl</td><td> F</td><td> I</td><td> F</td>

<td> .sec-butyl</td><td> Cl</td><td> I</td><td> F</td>

<td> .sec-butyl</td><td> F</td><td> Br</td><td> F</td>

<td> .sec-butyl</td><td> Cl</td><td> Br</td><td> F</td>

<td> .sec-butyl</td><td> F</td><td> ch3</td><td> F</td>

<td> .sec-butyl</td><td> Cl</td><td> ch3</td><td> F</td>

<td> .sec-butyl</td><td> F</td><td> cf3</td><td> F</td>

<td> sec-butyl</td><td> Cl</td><td> cf3</td><td> F</td>

WO 2007/014011

PCT/US2006/028326

WO 2007/014011

PCT/US2006/028326

WO 2007/014011

PCT/US2006/028326

WO 2007/014011

PCT/US2006/028326

<td> CHzCHzCHr-0-</td><td> Cl</td><td> I</td><td> F</td>

<td> ch2ch2-cKvoh %H</td><td> F</td><td> Br</td><td> F</td>

<td> CH2CH2-OxVOH ΌΗ</td><td> Cl</td><td> Br</td><td> F</td>

<td> CHjCHrO^V0^4 ΌΗ</td><td> Cl</td><td> cf3</td><td> F</td>

WO 2007/014011

PCT/US2006/028326

WO 2007/014011

PCT/US2006/028326

Tables 4a and 4b present species according to formula I, where A = Rid, except where 5 Rid is heterocyclic; compounds of that type are presented in Table 5. Each line in the table corresponds to five species which differ only at position Y.

TABLE 4a

SPECIES CORRESPONDING TO A = R1d

A’

A-V

F

Ya = CH3;Yb = Br;Yc = I;Yd = Cl;

WO 2007/014011

PCT/US2006/028326

TABLE 2B

<td> l(a-d)</td><td> H,H</td><td> H</td><td> 2-furanyl</td>

<td> 2(a-d)</td><td> H,H</td><td> H</td><td> 1,2,3 triazolyl-4-yl</td>

<td> 3(a-d)</td><td> H,H</td><td> H</td><td> 4-imidazolyl</td>

<td> 4(a-d)</td><td> H,H</td><td> H</td><td> 2-furanyl</td>

<td> 5(a-d)</td><td> H,H</td><td> H</td><td> 1,2,3 triazolyl-4-yl</td>

<td> 6(a-d)</td><td> H,H</td><td> H</td><td> 4-imidazolyl</td>

<td> 7(a-d)</td><td> H,H</td><td> -CH2CH(OH)CH2OH</td><td> 2-furanyl</td>

<td> 8(a-d)</td><td> H,H</td><td> -CH2CH(OH)CH2OH</td><td> 1,2,3 triazolyl-4-yl</td>

<td> 9(a-d)</td><td> H,H</td><td> -CH2CH(OH)CH2OH</td><td> 4-imidazolyl</td>

<td> 10(a-d)</td><td> -(CH2)2-</td><td> -CH2(C3H5)</td><td> 2-furanyl</td>

<td> ll(a-d)</td><td> -(CH2)2-</td><td> -CH2(C3H5)</td><td> 1,2,3 triazolyI-4-y 1</td>

<td> 12(a-d)</td><td> -(CH2)2-</td><td> -CH2(C3H5)</td><td> 4-imidazolyl</td>

<td> 13(a-d)</td><td> -(CH2)2-</td><td> ch3</td><td> 4-thiazolyl</td>

<td> 14(a-d)</td><td> -<ch2)2-</td><td> -ch2ch2oh</td><td> 4-thiazolyl</td>

<td> 15(a-d)</td><td> -(CH2)2-</td><td> -(CH2)2CH(OH)CH2OH</td><td> 4-thiazolyl</td>

<td> 16(a-d)</td><td> ch3,h</td><td> -(CH2)2CH(OH)CH2OH</td><td> 4-thiazolyl</td>

<td> 17(a-d)</td><td> -(CH2)2-</td><td> ch3</td><td> 2-oxazolyl</td>

<td> 18(a-d)</td><td> -(CH2)2-</td><td> -ch2ch2oh</td><td> 2-oxazolyl</td>

<td> 19(a-d)</td><td> -(CH2)2-</td><td> -(CH2)2CH(OH)CH2OH</td><td> 2-oxazolyl</td>

<td> 20(a-d)</td><td> ch3,h</td><td> -(CH2)2CH(OH)CH2OH</td><td> 2-oxazolyl</td>

Table 5 presents species of formulas Π-A, and III-A, and also species of generic formula ED-1, where Rid is a saturated heterocyclic group. Each line in the table corresponds to five species which differ only at position Y. Following the table, representative species are presented by structural formula, and labeled with the corresponding Compound Number from the table. Compounds la-74d, 85a-86d, and 93a-94d are representative of compounds where G is phenyl; compounds 37a-38d, 77a-82d, 87a-92d, 95a-l 12d, and 115a-l 16d are representative of formula U; compounds 127a-l 30d and 137a-142d are representative of formula II; compounds 113a-l 14d and 131 a-136d of formula ΙΠ; compounds 117a-124d of formula IV; and compounds 125a-126d of formula. V.

WO 2007/014011

PCT/US2006/028326

Table 5 Species of Generic Formulas ID-1, Π-A and ΠΙ-Α

Ya = SCH3; Yb = Br; Yc = I; Yd = CI; Ye= CH3

<td> Compound #</td><td> A = Rid, Αη, or Ar2</td><td> X</td>

<td> 1 (a-e)</td><td> phenyl</td><td> Cl</td>

<td> 2 (a-e)</td><td> phenyl</td><td> F</td>

<td> 3 (a-e)</td><td> 2-F-phenyl</td><td> Cl</td>

<td> 4 (a-e)</td><td> 2-F-phenyl</td><td> F</td>

<td> 5 (a-e)</td><td> 3-F-phenyl</td><td> Cl</td>

<td> 6 (a-e)</td><td> 3-F-phenyl</td><td> F</td>

<td> 7 (a-e)</td><td> 4-F-phenyl</td><td> Cl</td>

<td> 8 (a-e)</td><td> 4-F-phenyI</td><td> F</td>

<td> 9 (a-e)</td><td> 2,4-di-F-phenyl</td><td> Cl</td>

<td> 10 (a-e)</td><td> 2,4-di-F-phenyl</td><td> F</td>

<td> 11 (a-e)</td><td> 2,5-di-F-phenyl</td><td> Cl</td>

<td> 12 (a-e)</td><td> 2,5-di-F-phenyl</td><td> F</td>

<td> 13 (a-e)</td><td> 2,6-di-F-phenyl</td><td> Cl</td>

<td> 14 (a-e)</td><td> 2,6-di-F-phenyl</td><td> F</td>

<td> 15 (a-e)</td><td> 3,4-di-F-phenyl</td><td> Cl</td>

<td> 16 (a-e)</td><td> 3,4-di-F-phenyl</td><td> F</td>

<td> 17 (a-e)</td><td> 3,5-di-F-phenyl</td><td> CI</td>

<td> 18 (a-e)</td><td> 3,5-di-F-phenyl</td><td> F</td>

<td> 19 (a-e)</td><td> 2,6-di-F-phenyl</td><td> Cl</td>

<td> 20 (a-e)</td><td> 2,6-di-F-phenyl</td><td> F</td>

<td> 21 (a-e)</td><td> 2,3,4-tri-F-phenyl</td><td> Cl</td>

<td> 22 (a-e)</td><td> 2,3,4-tri-F-phenyl</td><td> F</td>

<td> 23 (a-e)</td><td> 3,4,5-tri-F-phenyl</td><td> Cl</td>

<td> 24 (a-e)</td><td> 3,4,5-tri-F-phenyl</td><td> F</td>

<td> 25 (a-e)</td><td> penta-F-phenyl</td><td> Cl</td>

<td> 26 (a-e)</td><td> penta-F-phenyl</td><td> F</td>

<td> 27 (a-e)</td><td> 3-Cl-4-F-phenyl</td><td> Cl</td>

<td> 28 (a-e)</td><td> 3-Cl-4-F-phenyl</td><td> F</td>

<td> 29 (a-e)</td><td> 2-Cl-4-F-phenyl</td><td> Cl</td>

<td> 30 (a-e)</td><td> 2-Cl-4-F-phenyl</td><td> F</td>

<td> 31 (a-e)</td><td> 2-F-3-Cl-phenyl</td><td> Cl</td>

WO 2007/014011

PCT/US2006/028326

<td> Compound #</td><td> A = Rm, Αη, or Ar2</td><td> X</td>

<td> 32 (a-e)</td><td> 2-F-3-Cl-phenyl</td><td> F</td>

<td> 33 (a-e)</td><td> 2-F-4-Cl-phenyl</td><td> Cl</td>

<td> 34 (a-e)</td><td> 2-F-4-Cl-phenyl</td><td> F</td>

<td> 35 (a-e)</td><td> 2-F-5-Cl-phenyl</td><td> Cl</td>

<td> 36 (a-e)</td><td> 2-F-5-Cl-phenyl</td><td> F</td>

<td> 37 (a-e)</td><td> 3 -cyano-4-F-phenyl</td><td> Cl</td>

<td> 38 (a-e)</td><td> 3-cyano- 4-F-phenyl</td><td> F</td>

<td> 39 (a-e)</td><td> 2-Cl-phenyl</td><td> Cl</td>

<td> 40 (a-e)</td><td> 2-Cl-phenyl</td><td> F</td>

<td> 41 (a-e)</td><td> 3-Cl-phenyl</td><td> Cl</td>

<td> 42 (a-e)</td><td> 3-Cl-phenyl</td><td> F</td>

<td> 43 (a-e)</td><td> 4-Cl-phenyl</td><td> Cl</td>

<td> 44 (a-e)</td><td> 4-Cl-phenyl</td><td> F</td>

<td> 45 (a-e)</td><td> 2,3-di-Cl-phenyl</td><td> Cl</td>

<td> 46 (a-e)</td><td> 2,3-di-Cl-phenyl</td><td> F</td>

<td> 47 (a-e)</td><td> 2,5-di-Cl-phenyl</td><td> Cl</td>

<td> 48 (a-e)</td><td> 2,5-di-Cl-phenyl</td><td> F</td>

<td> 49 (a-e)</td><td> 2,6-di-Cl-phenyl</td><td> Cl</td>

<td> 50 (a-e)</td><td> 2,6-di-Cl-phenyl</td><td> F</td>

<td> 51 (a-e)</td><td> 3,5-di-Cl-phenyl</td><td> Cl</td>

<td> 52 (a-e)</td><td> 3,5-di-Cl-phenyl</td><td> F</td>

<td> 53 (a-e)</td><td> 2,4-di-Cl-phenyl</td><td> Cl</td>

<td> 54 (a-e)</td><td> 2,4-di-Cl-phenyl</td><td> F</td>

<td> 55 (a-e)</td><td> 3,4-di-Cl-phenyl</td><td> Cl</td>

<td> 56 (a-e)</td><td> 3,4-di-Cl-phenyl</td><td> F</td>

<td> 57 (a-e)</td><td> 2,4,6-tri-Cl-phenyl</td><td> Cl</td>

<td> 58 (a-e)</td><td> 2,4,6-tri-Cl-phenyl</td><td> F</td>

<td> 59 (a-e)</td><td> 2-Cl-4-CF3-phenyl</td><td> Cl</td>

<td> 60 (a-e)</td><td> 2-Cl-4-CF3-phenyl</td><td> F</td>

<td> 61 (a-e)</td><td> 2-CF3-phenyl</td><td> Cl</td>

<td> 62 (a-e)</td><td> 2-CF3-phenyl</td><td> F</td>

<td> 63 (a-e)</td><td> 3-CF3-phenyl</td><td> Cl</td>

<td> 64 (a-e)</td><td> 3-CF3-phenyl</td><td> F</td>

<td> 65 (a-e)</td><td> 4-CF3-phenyl</td><td> Cl</td>

<td> 66 (a-e)</td><td> 4-CF3-phenyl</td><td> F</td>

<td> 67 (a-e)</td><td> 2-CF3O phenyl</td><td> Cl</td>

<td> 68 (a-e)</td><td> 2-CF3O phenyl</td><td> F</td>

<td> 69 (a-e)</td><td> 3-CF3O phenyl</td><td> Cl</td>

<td> 70 (a-e)</td><td> 3-CF3O phenyl</td><td> F</td>

<td> 71 (a-e)</td><td> 4-CF3O phenyl</td><td> Cl</td>

<td> 72 (a-e)</td><td> 4-CF3O phenyl</td><td> F</td>

<td> 73 (a-e)</td><td> 4-CHF2O-phenyl</td><td> Cl</td>

<td> 74 (a-e)</td><td> 4-CHF2O-phenyl</td><td> F</td>

<td> 75 (a-e)</td><td> 2-methyl-5 -nitro-phenyl</td><td> Cl</td>

<td> 76 (a-e)</td><td> 2-methyl-5-nitro-phenyl</td><td> F</td>

<td> 77 (a-e)</td><td> 2-cyano-phenyl</td><td> Cl</td>

WO 2007/014011

PCT/US2006/028326

<td> Compound #</td><td> A = Rid, Αη, or Ar2</td><td> X</td>

<td> 78 (a-e)</td><td> 2-cyano-phenyl</td><td> F</td>

<td> 79 (a-e)</td><td> 3-cyano-phenyl</td><td> Cl</td>

<td> 80 (a-e)</td><td> 3-cyano-phenyl</td><td> F</td>

<td> 81 (a-e)</td><td> 4-cyano-phenyl</td><td> Cl</td>

<td> 82 (a-e)</td><td> 4-cyano-phenyl</td><td> F</td>

<td> 83 (a-e)</td><td> 4-methoxy-phenyl</td><td> Cl</td>

<td> 84 (a-e)</td><td> 4-methoxy-phenyl</td><td> F</td>

<td> 85 (a-e)</td><td> 3,4-dimethoxy-phenyl</td><td> Cl</td>

<td> 86 (a-e)</td><td> 3,4-dimethoxy-phenyl</td><td> F</td>

<td> 87 (a-e)</td><td> 3-carbamyl-phenyl</td><td> Cl</td>

<td> 88 (a-e)</td><td> 3 -carbamyl-phenyl</td><td> F</td>

<td> 89 (a-e)</td><td> 3 -carboxyl-phenyl</td><td> Cl</td>

<td> 90 (a-e)</td><td> 3-carboxyl- phenyl</td><td> F</td>

<td> 91 (a-e)</td><td> 3 -(N,N-dimethylcarbamoyl)phenyl</td><td> Cl</td>

<td> 92 (a-e)</td><td> 3-(N,N-dimethylcarbamoyl)phenyl</td><td> F</td>

<td> 93 (a-e)</td><td> 4-methylsulfonyl-phenyl</td><td> Cl</td>

<td> 94 (a-e)</td><td> 4-methylsulfonyl-phenyl</td><td> F</td>

<td> 95 (a-e)</td><td> 3-(1,3,4 oxadiazol-2-yl)phenyl</td><td> Cl</td>

<td> 96 (a-e)</td><td> 3-(1,3,4 oxadiazol-2-yl)phenyl</td><td> F</td>

<td> 97 (a-e)</td><td> 3-(1,3,4 thiadiazol-2-yl)phenyl</td><td> Cl</td>

<td> 98 (a-e)</td><td> 3-(1,3,4 thi.adiazol-2-yl)phenyl</td><td> F</td>

<td> 99 (a-e)</td><td> 3 -(5-methyl-1,3,4-oxadiazol)phenyl</td><td> Cl</td>

<td> 100 (a-e)</td><td> 3-(5 -methyl-1,3,4-oxadiazol)phenyl</td><td> F</td>

<td> 101 (a-e)</td><td> 3-(5-methyl-1,3,4-thiadiazol)phenyl</td><td> Cl</td>

<td> 102 (a-e)</td><td> 3-(5 -methyl-1,3,4-thiadiazol)phenyl</td><td> F</td>

<td> 103 (a-e)</td><td> 3-amidinyI-phenyl</td><td> Cl</td>

<td> 104 (a-e)</td><td> 3-amidinyl-phenyl</td><td> F</td>

<td> 105 (a-e)</td><td> 3-(1 H-tetrazolyl)phenyl</td><td> Cl</td>

<td> 106 (a-e)</td><td> 3-(lH-tetrazolyl)phenyl</td><td> F</td>

<td> 107 (a-e)</td><td> 4-acetamido-phenyl</td><td> Cl</td>

<td> 108 (a-e)</td><td> 4-acetamido-phenyl</td><td> F</td>

<td> 109 (a-e)</td><td> 3-Cl-4-[(N-morpholinylcarbonyl) amino]phenyl</td><td> Cl</td>

<td> 110 (a-e)</td><td> 3 -Cl-4- [(N-morpholinylcarbony 1) amino]phenyl</td><td> F</td>

<td> 111 (a-e)</td><td> 3-Cl-4-[(N-pyrrolidinylcarbonyl) amino]phenyl</td><td> Cl</td>

<td> 112 (a-e)</td><td> 3-Cl-4-[(N-pyrrolidinylcarbonyl) amino]phenyl</td><td> F</td>

<td> 113 (a-e)</td><td> 3,5-dimethylisoxazoIyl</td><td> Cl</td>

<td> 114 (a-e)</td><td> 3,5-dimethylisoxazolyl</td><td> F</td>

<td> 115 (a-e)</td><td> 4-(N-morpholinylsulfonyl)phenyl</td><td> Cl</td>

<td> 116 (a-e)</td><td> 4-(N-morpholinylsulfonyl)phenyl</td><td> F</td>

<td> 117 (a-e)</td><td> 3-F-benzyl</td><td> Cl</td>

<td> 118 (a-e)</td><td> 3-F-benzyl</td><td> F</td>

<td> 119 (a-e)</td><td> 4-F-benzyl</td><td> Cl</td>

WO 2007/014011

PCT/US2006/028326

<td> Compound #</td><td> A = Rid, Ah, or Ar2</td><td> X</td>

<td> 120 (a-e)</td><td> 4-F-benzyl</td><td> F</td>

<td> 121 (a-e)</td><td> 3-F-phenyl-ethyl</td><td> Cl</td>

<td> .122 (a-e)</td><td> 3-F-phenyl-ethyl</td><td> F</td>

<td> 123 (a-e)</td><td> 4-F-phenyl-ethyl</td><td> Cl</td>

<td> 124 (a-e)</td><td> 4-F-phenyl-ethyl</td><td> F</td>

<td> 125 (a-e)</td><td> 8-quinolinyl</td><td> CI</td>

<td> 126 (a-e)</td><td> 8-quinolinyl</td><td> F</td>

<td> 127 (a-e)</td><td> 2-thienyl</td><td> Cl</td>

<td> 128 (a-e)</td><td> 2-thienyl</td><td> F</td>

<td> 129 (a-e)</td><td> 2,3 -di-Cl-thien-5 -yl</td><td> Cl</td>

<td> 130 (a-e)</td><td> 2,3-di-Cl-thien-5-yl</td><td> F</td>

<td> 131 (a-e)</td><td> 1,3,5 trimethyl-lH-pyrazolyl</td><td> Cl</td>

<td> 132 (a-e)</td><td> 1,3,5 trimethyl-lH-pyrazolyl</td><td> F</td>

<td> 133 (a-e)</td><td> 1,3 -dimethyl-5-Cl-1 H-pyrazolyl</td><td> Cl</td>

<td> 134 (a-e)</td><td> 1,3-dimethyl-5-Cl-lH-pyrazolyl</td><td> F</td>

<td> 135 (a-e)</td><td> 1 -methyl-3 -CF3-1 H-pyrazol-4-yl</td><td> Cl</td>

<td> 136 (a-e)</td><td> 1 -methyl-3 -CF3-lH-pyrazol-4-yl</td><td> F</td>

<td> 137 (a-e)</td><td> 2-acetamido-4-methyl-thiazol-5-yl</td><td> Cl</td>

<td> 138 (a-e)</td><td> 2-acetamido-4-methyi-thiazol-5-yi</td><td> F</td>

<td> 139 (a-e)</td><td> 2,4-dimethyl-thiazol-5-yl</td><td> Cl</td>

<td> 140 (a-e)</td><td> 2,4-dimethyl~thiazol-5-yl</td><td> F</td>

<td> 141 (a-e)</td><td> 1,2-dimethyl-1 H-imidazol-4-y 1</td><td> Cl</td>

<td> 142 (a-e)</td><td> 1,2-dimethyl-lH-imidazol-4-yl</td><td> F</td>

Synthetic Procedures and Examples

Compounds of this invention can be prepared by a variety of methods. The procedures below are intended to illustrate those methods, and the examples given are intended to illustrate the scope of this invention. Neither the methods not the examples should be construed as limiting the invention in any way.

I. The preparation of compound of formula VI is outlined below

WO 2007/014011

PCT/US2006/028326

Scheme I above illustrates the preparation of sulfonamide derivatives of formula VI. 1,2 Diamine derivative (formula IV) can be easily prepared in two steps from the desired nitro derivatives (formula I). Compounds of formula IV can be reacted with the sulfonyl chloride derivatives (formula V, see next scheme) to form the desired sulfonamide. Alternatively, the 1,2 diamine derivatives IV can be protected to for an imidazolidone (formula VII), before being reacted with the corresponding sulfonyl chloride. Deprotection of the 1,2 diamine VEff under basic conditions provided the desired material VI.

Π. The general route to synthesis compound of general formula V is outlined below

XII v

WO 2007/014011

PCT/US2006/028326

Scheme II above shows one example of the preparation of complex sulfonyl chloride.

Compound XX can be synthesized from IX, alleylated, and converted to the potassium salt

ΧΠ. Treatment of the salt with SOC12 or POCI3 affords the desired compounds. Other more specific procedures to prepare unique sulfonyl chloride derivatives are reported in the experimental section.

The following examples are provided so that the invention might be more fully understood. These examples are illustration of the scope of the invention only and should not be construed as limiting the invention in any way.

Typical procedures for the synthesis of su lfonamides:

Procedure A: To a solution of the amine (1 eq) in anhydrous dichloromethane (3 mL/ mmole) was added anhydrous triethylamine (5 eq). To this solution was added the sulfonyl chloride (1 eq) and the solution was stirred at room temperature for 16 h. The solvent was evaporated and the residue was purified by flash column chromatography on silica.

Procedure B: To a stirred solution of the amine (1 eq) in anhydrous pyridine (5ml/mmole) was added the sulfonyl chloride (1-5 eq). The reaction mixture was stirred at 40 20 °C for 48 hours. The reaction mixture was partitioned with water and EtOAc. The organic layer was washed with brine, dried (MgSCU) and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica.

Example 1

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)methanesulfonamide:

Step A: 2.3-Difluoro-N-(2-fluoro-4-iodophenvl)-6-nitroaniline:

To a solution of 2-fluoro-4-iodoaniline (11.40 g, 47 mmol) in 100 ml anhydrous THF at 0 °C, 47 ml of a 1M solution of LHMODS in THF (47 mmol) was added dropwise. The

WO 2007/014011

PCT/US2006/028326 color of the solution turned dark purple. The solution was transferred via cannula to a dropping funnel, and the solution (containing the amine free base) was added in small portions to a solution of 2,3,4-trifluoronitrobenzene (8.321 g, 47.0 mmol) in anhydrous THF (50 ml) at 0 °C. After completion of addition the mixture was stirred under argon at room temperature for 15 hours. The volume of the solvent was reduced, followed by extraction using ethyl acetate and brine. The organic layer was dried over sodium sulfate, the solvent was removed, and the obtained dark oil was purified by flash chromatography (EtOAc / hexane 1:5, Rf= 0.58) yielding the crude product, which became a brown solid upon drying in vacuo (yield: 6.23 g, 33.6%). m/z = 393 [M-l]'.

Step B: 5,6-Difluoro-Nl-(2-fluoro-4-iodophenyl')benzene-1.2-diamine

To a solution of nitro-diarylamine (6.23 g, 15.8 mmol) in 300 ml ethanol was added iron powder (13.74 g, 246 mmol) and ammonium chloride (13.59 g, 254 mmol) and the mixture was heated with stirring at 100 °C oil bath temperature for 14 hours. It was filtered and the residue washed two times with ethanol. The ethanol was removed in vacuo, and the residue was extracted using ethyl acetate / 1M NaOH solution. During the extraction, more precipitate was formed which was filtered and discarded. The combined organic layers were washed with brine and dried over sodium sulfate. The solvent was removed, and the crude product was recrystallized from CHC13 / hexane (1:50). The product was obtained as brown needles (2.094 g, 66%,). Rf = 0.44 (EtOAc / Hex 1:3). 'H-NMR (500 MHz, CDC13): 5 = 7.40 7.38 (dd, 1H, 7= 11.3 Hz, 7= 1.5 Hz). 7.25-7.23 (d, 1H,7= 8.5 Hz), 6.97-6.92 (q, 1H, 7= 9

Hz), 6.51-6.48 (m, 1H), 6.24-6.21 (t, 1H, 7= 9 Hz), 5.3 (s, 1H, NH, br), 3.80 (s, 2H, NHZ, br); LRMS (ESI): m/z = 365 [M+H]+.

Step C: N-(3,4-difluoro-2-f2-fluoro-4-iodophenylamino') phenyl) methanesulfonamide:

WO 2007/014011

PCT/US2006/028326

According to the general procedure A, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzene-1,2-diamine was reacted with methanesulfonyl chloride to obtain the desired product. ’HNMR: (500 MHz, CDC13): δ = 7.38-7.37 (d, 1H), 7.35-7.34 (m, 1H), 7.27-7.26 (m, 1H), 7.20-7.0 (q, 1H), 6.68 (s, 1H, br), 6.15-6.12 (q, 1H), 5.65 (s, 1H, br), 2.95 (s, 3H); zw/z = 441 [M-1]'.

Example 2

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)cycIopropanesuIfonamide:

According to the general procedure A, 5,6-difluoro-Nl-(2-fluoro-4-iodophenyl) benzene-1,2-diamine was reacted with cyclopropanesulfonyl chloride to obtain the desired product. ’H NMR: (500 MHz, CDC13): δ = 7.38-7.37 (d, 1H), 7.35-7.34 (m, 1H), 7.27-7.26 (m, 1H), 7.20-7.0 (q, 1H), 6.68 (s, 1H, br), 6.15-6.12 (q, 1H), 5.65 (s, 1H, br), 3.25-3.20 (m, 1H), 2.4-2.3 (m, 2H), 2.0-1.8 (m, 2H); m/z = 467 [M-1]’.

Example 3

N-(3,4-difIuoro-2-(2-fluoro-4-iodophenylamino)phenyl)propane-2-suIfonamide:

WO 2007/014011

PCT/US2006/028326

According to the general procedure A, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzene-l,2-diamine was reacted with isopropylsulfonyl chloride to obtain the desired product. Yield: 39%. ’H-NMR (500 MHz, CDC13): δ = 7.50-7.43 (m, 1H), 7.35-7.34 (m, 1H), 7.27-7.26 (m, 1H), 7.15-7.09 (q, 1H, J= 1.6 Hz), 6.62 (s, 1H, br), 6.22-6.18 (q, 1H, 7= 1.5 Hz), 5.65 (s, 1H, br), 3.30-3.28 (m, 1H), 1.38-1.37 (d, 6H, 7= 1.2 Hz); m/z = 469 [Μι]'

Example 4

N-(3,4-difluoro-2-(2-flnoro-4-iodophenylamino)phenyl)butane-l-sulfonamide:

According to the general procedure A, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzene-l,2-diamine was reacted with n-butylsulfonyl chloride to obtain the desired product. Yield: 55%. 'H-NMR (500 MHz, CDC13): δ = 7.50-7.43 (m, 1H), 7.35-7.34 (m, 1H), 7.27-7.26 (m, 1H), 7.15-7.09 (q, 1H, J= 1.6 Hz), 6.62 (s, 1H, br), 6.22-6.18 (q, 1H, 7= 1.5 Hz), 5.65 (s, 1H, br), 3.06-3.031 (t, 2H, 7= 1.4 Hz), 1.75-1.71 (m, 2H), 1.38-1.36 (m, 2H), 0.87-0.86 (t, 3H, 7= 1.3 Hz); m/z = 483 [M-l]'.

Example 5

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylainino)phenyl)-2,2,2-trifluoro ethane sulfonamide:

WO 2007/014011

PCT/US2006/028326

According to the general procedure A, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzene-l,2-diamine was reacted with 1,1,1 -trifluoroethylsulfonyl chloride to obtain the desired product. Yield: 28%. m/z = 509 [M-l]'.

Example 6

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)butane-2-sulfonamide:

According to the general procedure A, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzene-l,2-diamine was reacted with sec-butylsulfonyl chloride to obtain the desired product. Yield: 22%. ’H-NMR (500 MHz, MeOH[d4]): δ = 7.60-7.40 (m, 3H), 7.187.00 (q, 1H), 6.55-6.45 (m, 1H), 3.55-3.50 (m, 1H), 2.20-2.00 (m, 1H), 1.80-1.60 (m, 1H), 1.43-1.40 (d, 3H), 1.06-1.04 (t. 3H); wt/z = 483 [M-l]'.

Example 7

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-N-methyl cyclopropane sulfonamide:

WO 2007/014011

PCT/US2006/028326

To a solution of N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)cyclopropanesulfonamide (see Example 2) (283.9 mg, 0.61 mmol) in 3 ml anhydrous THF was added at -78 °C a 1M solution of LHMDS (0.6 ml, 0.6 mol) and the solution was stirred for 10 min at this temperature. Then, methyl iodide (0.8 ml, 1.824 g, 12.9 mmol) was added and the mixture was warmed to room temperature and stirred for 7 h. The solvent was removed and the residue extracted using EtAc and brine. The organic fractions were dried using Na2SC>4 and the solvent was removed. The obtained crude product was purified using flash-column chromatography (Si, EtAc/Hexanes 1:2, Rf= 0.45). Yield: 205 mg, 70%). ’H-NMR (500 MHz, CDC13): δ = 7.41-7.39 (d, 1H, J= 10 Hz), 7.30-7.29 (d, 1H, J= 8.0 Hz), 7.23-7.20 (m, 1H), 6,98-6.93 (q,

1H, 7=8.5 Hz), 6.60 (s, 1H, br), 6.51-6.47 (m, 1H), 3.23 (s, 3H), 2.46-2.42 (m, 1H), 1.19-1.16 (m, 2H), 1.04-1.02 (m, 2H); tn/z = 481 [M-l]'.

Example 8 l-Chloro-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl) methane sulfonamide:

F

According to the general procedure A, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzene-l,2-diamine was reacted with chloromethanesulfonyl chloride to obtain the desired product, m/z = 475 [M-l]'.

Example 9

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-2-methylpropane-225 sulfonamide:

WO 2007/014011

PCT/US2006/028326

According to the general procedure B, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzene-l,2-diamine was reacted with 2-methylpropane-2-sulfonyl chloride (synthesized according to the literature procedure) to obtain the desired product. ’H NMR (300 MHz, CDC13): δ 7.50 (m, 1H), 7.43 (dd, J= 1.8 & 10.5 Hz, 1H), 7.28 (br s, 1H), 7.10 (dd, J= 9.0 & 17.7 Hz, 1H), 6.48 (br s, D2O exchangeable, 1H), 6.19 (t, J= 7.8 & 9.6 Hz, 1H), 5.58 (br s, D2O exchangeable, 1H), 1.39 (s, 9H); m/z = 383 [M-l]’.

Example 10

N-(3,4-difluoro-2-(2-fluoro-4-iodophenyIamino)phenyl)cyclopentanesulfonamide:

According to the general procedure B, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzene-l,2-diamine was reacted with cyclopentanesulfonyl chloride to obtain the desired product Ή NMR (300 MHz, CDC13): δ 7.42 (dd, /= 2.1 & 10.5 Hz, 1H), 7.36 (ddd, J= 2.4,4.8, & 9.3 Hz, 1H), 7.25 (m, 2H), 7.10 (dd, /= 9.6 & 17.7 Hz, 1H), 6.67 (br s, D2Oexchangeable, 1H), 6.20 (dt, /= 1.5, 8.4 & 17.4 Hz, 1H), 3.53 (p, 1H), 1.80 (m, 8H); m/z =495 [M-l]’.

Example 11

N-(3,4-difluoro-2-(2-fluoro-4-iodophenyIamino)phenyl)cyclohexanesulfonamide:

WO 2007/014011

PCT/US2006/028326

According to the general procedure B, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzene-l,2-diamine was reacted with cyclohexanesulfonyl chloride to obtain the desired product. *H NMR (300 MHz, CDC13): δ 7.43 (dd, J= 1.5 & 10.2 Hz, 1H), 7.37 (ddd, J = 2.4, 4.8 & 9.6 Hz, 1H), 7.27 (m, 1H), 7.11 (dd, J=9.3& 18.0 Hz, 1H), 6.64 (br s, 1H), 6.18 (dt, J= 1.5, 9.0 & 17.4 Hz, 1H), 5.63 (br s, 1H), 2.95 (triplet of triplet, 2.10-1.16 (m, 10H); zw/z = 509 [M-l]’.

Example 12

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-l-methylcyclopropane-lsulfonamide:

Step A: n-Butyl 3-chloro-l -propanesulfonate:

cr ~Os00 0-nBu

Triethylamine (28 ml, 200 mmol) in CH2CI2 (50 ml) was slowly added to an icecooled solution of 3-chloro-1-propanesulfonyl chloride (36.6g, 200 mmol) and 1-butanol (18.4 g, 240 m mol) in CH2CI2 (250 ml) and stirring was continued for 16h. The mixture was diluted with CH2CI2 (200 ml), washed (aqueous HCI) and dried (MgSO4) and the solvent was evaporated to obtain the titled product 1 (40.85 g, 95%) in crude form as slightly yellow oil which was used for the next reaction without further purification. *H NMR (CDC13)) δ 0.94 (t, J = 7.5 Hz, 3H), 1.44 (sextet, 2H), 1.72 (quintet, 2H), 2.31 (quintet, 2H), 3.27(t, J = 6.9 Hz,

2H), 3.68 (t, J = 6.3 Hz), 4.23 (t, J = 6.6 Hz, 2H).

Step B: 1-Butyl cyclopropanesulfonate:

WO 2007/014011

PCT/US2006/028326

O-nBu

Solutions of 1-butyl 3-chloro-l-propanesulfonate (4.6 g, 21.39 mmol in 25 ml THF) and of butyllithium (14.7 ml, 23.53 mmol, 1.6M, THF) were simultaneously added to THF (150 ml) at -78 °C under nitrogen atmosphere. The solution was allowed to warm to 0 °C and then quenched with water (2 ml). The volatiles evaporated under reduced pressure and the residue extracted with CH2CI2 (150 ml). The extract was washed with water and dried (MgSOzt) and evaporated to give crude desired product (3.23 g, 78.22%) in almost pure form as pale yellow oil which was used for next step without further purification. ]H NMR (300

MHz, CDC13) δ 0.94 (t, J = 7.5 Hz, 3H), 1.07 (m, 2H), 1.25 (m, 2H), 1.45(sextet, 2H),

1,74(quintet, 2H), 2.45 (heptet, 1H), 4.23 (t, J = 6.6 Hz, 2H).

Step C: Butyl 1 -Methyl-cyclopropanesulfonate:

O'O-nBu

To a solution of 1-Butyl cyclopropanesulfonate (1 g, 5.58 mmol) in THF (15 ml) butyllithium solution (3.84 ml, 6,14 mmol, 1.6M, THF) was slowly added at -78 °C under nitrogen atmosphere. After 15 minutes Mel (0.72 ml, 11.16 mmol) was added and the solution was allowed to warm to 0 °C and quenched with water (1 ml). The volatiles evaporated under reduced pressure and the residue extracted with CH2CI2 (100 ml). The extract was washed with water, dried (MgSC>4) and evaporated. The residue was purified over silica gel chromatography (eluants: hexane/ CH2CI2) to obtain the titled product (0.59 g, 55.0%) as a colorless oil. *H NMR (300 MHz, CDC13)) δ 0.84 (m, 2H), 0.95 (t, J = 7.2 Hz,

3H), 1.43 (m, 4H), 1.53 (s, 3H), 1.74(m, 2H), 4.21 ((t, J = 6.6 Hz, 2H).

Step D: 1 -Potassium 1 -Methyl-cyclopropanesulfonate:

WO 2007/014011

PCT/US2006/028326 °’όκ

A mixture of 1- Butyl 1-Methyl-cyclopropanesulfonate (0.386 g, 2 mmol) and potassium thiocyanate (0.194 g, 2 mmol) in DME (5 ml) and water (5 ml) was refluxed for

16h. The volatiles were evaporated to obtain the crude sulfonate (0.348g, quantitative) which was dried under vacuum at 50 °C for 16h. The crude product was used in the next reaction without further purification. 'H NMR (300 MHz, D2O) δ 0,56 (t, J = 6.3 Hz, 2H), 0.96 (t, J = 6.3 Hz, 2H), 1.26 (s, 3H).

Step E: l-Methyl-cyclopropanesulfonylchloride:

«Ο o 1 Cl

A solution of 1-potassium 1 -methyl-cyclopropanesulfonate (0.348 g, 2 mmol), thionyl chloride (5 ml) and DMF (5 drops) was refluxed at 60 °C for 16h. The volatiles evaporated under reduced pressure and the residue extracted with CH2C12 (50 ml). The extract was washed with water, dried (MgSO4) and evaporated to obtain the crude product as yellow gummy oil which was used in the next reaction without further purification.

Step F: N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-lmethylcyclopropane-1-sulfonamide:

According to the general procedure B, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzene-l,2-diamine was reacted with l-methyl-cyclopropanesulfonylchloride to

WO 2007/014011

PCT/US2006/028326 obtain the desired product. ’H NMR (300 MHz, CDC13): δ 7.42 (dd, /= 1.8 & 10.5 Hz, 1H), 7.36 (ddd, /= 2.4,4.5 & 9.0 Hz, 1H), 7.27 (d, /= 6.0 Hz, 1H), 7.07 (dd, /= 9.3 & 17.7 Hz, 1H), 6.24 (dt,/=2.1, 8.7 & 17.4 Hz, 1H), 5.86 (br s, 1H), 1.43 (s, 3H), 1.33 (t,/= 5.4 Hz, 2H), 0.75 (dd,/=5.1 & 6.3 Hz, 2H);w/z = 481 [M-l]'.

Example 13

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-l-(2,3-dihydroxypropyl) cyclopropane-l-sulfonamide:

Step A: Butyl cyclopropanesulfonate:

Cyclopropanesulfonyl chloride (5 g, 35 mmole, 1 eq) was dissolved in an excess BuOH (20 15 ml), the reaction mixture was cooled at -10 °C and pyridine (5.8 mL, 70 mmole, 2 eq) was slowly added dropwise. The mixture was slowly warmed at room temperature and stirred overnight. The solvent was removed under reduced pressure and the resulting white solid was dissolved in CHCI3. The organic phase was washed with water, brine and dried (MgSO4) and concentrated to give an oil (4.8 g, 24.9 mmole, 71%). ’H NMR (300 MHz,

CDCI3): δ 4.25 (t, 2H), 2.46 (m, 1H), 1.74 (m, 2H), 1.45 (m, 2H), 1.25 (dd, 2H), 1.09 (dd, 2H), .93 (t, 3H).

Step B: Butyl 1 -allylcyclopropane-1 -sulfonate:

To a solution of 1-butyl cyclopropanesulfonate (4.8 g, 24.9 mmole) in THF at - 78°C was added simultaneously butyllithium solution (15. 6 ml, 24.9 mmol, 1.6M, THF) and allyl iodide (24.9 mmole) under nitrogen atmosphere. The reaction mixture was stirred 2 hours at 30 78°C and 3 hours at room tempoerature. The volatiles were evaporated under reduced

WO 2007/014011

PCT/US2006/028326 pressure and the residue extracted with CH2C12 (100 ml). The extract was washed with water, dried (MgSOzi) and evaporated. The residue was purified over silica gel chromatography (eluants: hexane/ CH2C12) to obtain the titled product (3.75 g, 69.0%) as a colorless oil. ’H NMR (300 MHz, CDCI3): δ 5.6 (m, 1H), 5.13-5.08 (t, 2H), 4.21 (t, 2H), 2.65 (d, 2H), 1.7 (m,

2H), 1.4 (m, 4H), .93 (m, 5H).

Step C: Potassium 1-allylcvclopropane-l-sulfonate:

ΖΔΖ .O'K+

X

O 0

A mixture of 1- butyl 1-methyl-cyclopropanesulfonate (3.75 g, 17.2 mmol) and potassium thiocyanate (1.7 g, 17.2 mmol) in DME (20 ml) and water (20 ml) was refluxed for 16h. The volatiles were evaporated to obtain the crude sulfonate (3.44g, quantitative) which was dried under vacuum at 50 °C for 16h. The crude product was used in the next reaction without further purification. *H NMR (CDC13): δ 5.6 (m, 1H), 4.91-4.85 (dd, 2H), 2.471-2.397 (d, 2H), 0.756 (m, 2H), 0.322 (m, 2H).

Step D: l-allylcyclopropane-1-sulfonyl chloride:

o'A'o

A solution of potassium l-allylcyclopropane-1 -sulfonate (3.44 g, 17.2 mmol), thionyl chloride (10 ml) and DMF (5 drops) was refluxed at 60 °C for 16h. The volatiles evaporated under reduced pressure and the residue extracted with CH2C12 (50 ml). The extract was washed with water, dried (MgSCU) and evaporated to obtain the crude product as yellow gummy oil which was washed with hexane and used in the next reaction without further purification (2.7 g, 15 mmole, 87%). ^NMR (300 MHz, CDC13): δ 5.728 (m, 1H), 5.191 (t, 2H), 2.9 (d, 2H), 0.756 (m, 2H), 0.322 (m, 2H).

WO 2007/014011

PCT/US2006/028326

Step E: l-allyl-N-(3.4-difluoro-2-(2-fluoro-4-iodophenvlamino)phenvl)cvclopropane1-sulfonamide:

According to the general procedure B, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzene-l,2-diamine was reacted with 1-allylcyclopropane-l-sulfonyl chloride to obtain the desired product, m/z = 507 [M-1]'.

Step F: N-(3,4-difluoro-2-(2-fluoro· 4-iodophenylamino)phenvD-1 -(2,3dihydroxypropy Dcyclopropane-1 -sulfonamide:

l-Allyl-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino) phenyl)cyclopropane-lsulfonamide (0,77 g, 1.52 mmole) and 4-methylmorpholine N-oxide (0,18 g, 1.52 mmole) were dissolved in THF (50 mL). Osmium tetroxide was added at room temperature (0.152 mmole, 0.965 mL, 4% in H2O) and the reaction mixture was stirred at room temperature for

16 hours. EtOAc was added, the organic phase was washed with water, dried (MgSO4) and concentrated under reduced pressure. The residue was purified over silica gel chromatography (eluants: EtOAc/ MeOH) to obtain the titled product (0. 65 g, 79%). *H NMR (300 MHz, CDC13 + D2O): δ 7.38 (dd, J= 1.8 & 10.5 Hz, 1H), 7.36 (ddd, J= 2.4, 5.1 & 9.3 Hz, 1H), 7.25 (d, J= 8.7 Hz, 1H), 7.02 (dd, J= 9.0 & 17.7 Hz, 1H), 6.27 (dt, J= 3.0,

8.7 & 17.4 Hz, 1H), 3.92 (m, 1H), 3.54 (dd, 7=3.9 & 11.1 Hz, 1H), 3.39 (dd, 7=6.6 & 11.1

WO 2007/014011

PCT/US2006/028326

Hz, 1H), 2.16 (dd, J= 9.6 & 15.9 Hz, 1H), 1.59 (d,J= 14.1 Hz, 1H), 1.41 (m, 1H), 1.26 (m, 1H), 0.83 (m, 2H); m/z = 542 [M-l]'.

Example 14 (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodopheryIamino)phenyl)-l-(2,3dihydroxypropyl)cyclopropane-l-sulfonamide:

The pure S isomer was obtained by chiral HPLC separation of the racemic mixture (example 13). 'HNMR (300 MHz, CDC13 + D2O): δ 7.38 (dd, /= 1.8 & 10.5 Hz, 1H), 7.36 (ddd, J= 2.4, 5.1 & 9.3 Hz, 1H), 7.25 (d, J= 8.7 Hz, 1H), 7.02 (dd, /= 9.0 & 17.7 Hz, 1H),

6.27 (dt, J= 3.0, 8.7 & 17.4 Hz, 1H), 3.92 (m, 1H), 3.54 (dd, J= 3.9 & 11.1 Hz, 1H), 3.39 (dd, /= 6.6 & 11.1 Hz, 1H), 2.16 (dd, J= 9.6 & 15.9 Hz, 1H), 1.59 (d, J= 14.1 Hz, 1H), 1.41 (m, 1H), 1.26 (m, 1H), 0.83 (m, 2H); m/z = 542 [M-l]'.

Example 15 (R)-N-(3,4-difluoro-2-(2-fluoro-4-iodopheaylamino)phenyl)-l-(2,3dihydroxypropyl)cyclopropane-l-sulfonamide:

The pure R isomer was obtained by chiral HPLC separation of the racemic mixture (example 13). ‘HNMR (300MHz, CDC13 + D2O): δ 7.38 (dd, J= 1.8 & 10.5 Hz, 1H), 7.36 (ddd, J= 2.4, 5.1 & 9.3 Hz, 1H), 7.25 (d, J= 8.7 Hz, 1H), 7.02 (dd, J= 9.0 & 17.7 Hz, 1H),

WO 2007/014011

PCT/US2006/028326

6.27 (dt, 7= 3.0, 8.7 & 17.4 Hz, 1H), 3.92 (m, 1H), 3.54 (dd, 7= 3.9 & 11.1 Hz, 1H), 3.39 (dd, 7= 6.6 & 11.1 Hz, 1H), 2.16 (dd, 7= 9.6 & 15.9 Hz, 1H), 1.59 (d, 7= 14.1 Hz, 1H), 1.41 (m, 1H), 1.26 (m, 1H), 0.83 (m, 2H); m/z = 542 [M-l].

Example 16

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-l-(2hydroxyethyl)cyclopropane-l-sulfonamide:

Step A: 2-(1 -bromocyclopropyOethanol:

ix.

OH

To a solution of neat diethyl zinc (3.3 ml, 3.977 g, 30 mmol) in 100 ml anhydrous DCM was added very slowly trifluoroacetic acid (2.31 ml, 3.4188 g, 30 mmol) dropwise at 0 °C. (Caution: Violent gas evolution, exothermic!). After completed addition of the TFA, the suspension was stirred for 20 min at the same temperature, followed by the addition of diiodo methane (2.45 ml, 8.134 g, 30.4 mmol). It was further stirred at 0 °C for 20 min, and then a solution of 3-bromobut-3-en-l-ol (1 ml, 1.523 g, 10.1 mmol) in 10 ml DCM was added at the same temperature. After complete addition, the mixture was warmed to room temperature and stirred for 4 hours. The mixture was quenched with 100 ml MeOH and 40 ml brine, and it was further stirred for 30 min. The solvents were reduced, and the residue extracted using CHCb / aq. NH4CI. The organic layers were collected, washed with brine and water, and the solvent was removed to give 2-(l-bromocyclopropyl)-ethanol in sufficient purity (1.6564 g, 100%). ’H-NMR (500 MHz, CDCI3): δ = 3.90-3.83 (t, 2H), 1.91-1.87 (t, 2H), 1.71 (s, 1H, br), 1.14-1.09 (m, 2H), 0.83-0.79 (m, 2H).

Step B: TBS protected 2-(1-bromocyclopropyOethanol:

OTB S

WO 2007/014011

PCT/US2006/028326

To a solution of the cyclopropyl alcohol (Step A) (1.303 g, 7.95 mmol) in 30 ml anhydrous DCM was added anhydrous pyridine (1.2 ml, 1,1736 g, 14.8 mmol) and TBSOTf (2.7 ml, 3.1077 g, 11.76 mol) and the solution was stirred at room temperature for 16 h. It was extracted with CHC!3 / brine and the organic fraction was dried with MgSO4. The solvent was reduced and the crude product purified using flash-column chromatography (Si, CHC13 / hexanes 1:10, Rf= 0.4). Yield: 0.796 g, 36%. ]H-NMR (500 MHz, CDC13): δ = 3.95-3.75 (t, 2H), 1.95-1.85 (t, 2H), 1.15-1.05 (m, 2H), 0.95-0.80 (m, 11H), 0.15-0.05 (s, 6H).

Step C: TBS protected 2-(l-chlorosulfonvlcyclopropyl)ethanol:

ZSO2CI XOTBS

To a solution ofthe cyclopropyl bromide prepared in step B (1.1227 g, 4.04 mmol) in 15 ml anhydrous diethyl ether was added a 1.7 M solution of t-BuLi in pentane (4.8 ml, 8.16 mmol) at - 78 °C. The solution was stirred for 30 min at this temperature, and was then transferred via a transfer canola into a solution of freshly distilled sulfuryl chloride (0.65 ml,

1.029 g, 8.1 mmol) in 8 ml diethyl ether at - 78 °C. The yellow suspension was warmed to room temperature. The solvent was removed, and the residue was dried in vacuo to remove excessive sulfuryl chloride. Then, the residue was extracted two times with hexane, and after filtration the solvent was evaporated in vacuo to give the sulfonyl chloride in sufficient purity as a colorless oil. Yield: 870 mg (72%). 'H-NMR (300 MHz, CDC13): δ = 3.95-3.85 (t, 2H), 2.35-2.25 (t, 2H), 1.80-1.70 (m, 2H), 1.45-1.38 (m, 2H), 0.90 (s, 9H), 0.10 (s, 6H).

Step D: TBS-protected N-f3.4-difluoro-2-(2-fluoro-4-iodophenvlamino,)phenvl)-l-(2hydroxvethvDcvclopropane-l-suifonamide:

WO 2007/014011

PCT/US2006/028326

According to the general procedure B, 5,6-difluoro-Nl-(2-fluoro-4-iodophenyl)benzene-l,2diamine was reacted with the cyclpropylsulfonyl chloride prepared in step C to obtain the desired product. ’H-NMR (300 MHz, CDC13): δ = 7.44-7.39 (dd, 1H), 7.32-7.24 (m, 2H), 7.16.98 (q, 1H), 6.34-6.24 (m, 1H), 6.16 (s, 1H, br), 3.85-3.75 (t, 2H), 2.15-2.00 (t, 2H), 1.35-1.20 (m, 2H), 0.95-0.75 (m, 11H), 0.10 (s, 6H); m/z = 625 [M-l]’.

Step E: Nr(3.4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-l-(210 hydroxyethy ^cyclopropane-1 -sulfonamide:

To a solution of the TBS-protected sulfonamide prepared in step D (21 mg, 0.033 mmol) in 1 15 ml THF was added 0.1 ml aq. 1.2N HCI solution at 0 °C and the solution was stirred for 2 h.

The solvents were reduced and the residue was extracted using aq. NaHCO3 solution and EtAc. The organic fractions were dried with MgSC>4 and the volatiles were removed. The crude product was purified using flash-column chromatography (Si, CHCI3 / MeOH 10:1, Rr = 0.45) to give the pure product. Yield: 16.9 mg (100%). 'H-NMR (300 MHz, CDC13): δ = 7.44-7.39 (dd, 1H), 7.32-7.24 (m, 2H), 7.1-6.98 (q, 1H), 6.34-6.24 (m, 1H), 6.16 (s, 1H, br), 3.85-3.75 (t, 2H), 2.15-2.00 (t, 2H), 1.35-1.20 (m, 2H), 0.95-0.85 (m, 2H); m/z = 511 [M-l]'.

Example 17

WO 2007/014011

PCT/US2006/028326

N-(3,4-difluoro-2-(2-fluoro-4-iodopkenylamino)phenyl)-3-hydroxypropane-lsulfonamide:

HO

F

To a solution of 3-Chloro-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-propane1-sulfonamide (69.4 mg, 0.138 mmol) in a mixture of 8 ml 1,4-dioxane and 2 ml H2O was added KOH powder (0.674 g, 12.0 mmol) and the mixture was heated to the reflux temperature for 3 days. It was extracted using EtAc / brine, the organic fraction was dried with Na2SO4 and the volatiles were removed. The residue was purified using flash-column chromatography (Si, DCMI MeOH 5:1, Rf = 0.3). Yield: 41 mg (62%). 'H-NMR (500 MHz, MeOH [d4]): δ = 7.387.21 (d, 1H), 7.23-7.21 (d, 1H), 7.06-7.00 (q, 1H), 6.52-6.50 (m, 1H). 6.17-6.13 (t, 1H), 3.303.27 (t, 2H), 2.86-2.83 (t, 2H), 2.05-2.00 (m, 2H); wi/z = 485 [M-l]'.

Example 18

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-2-methyI-5(trifluoromethyl)furan-3-sulfonamide:

H;

According to the general procedure 5,6-difluoro-Nl-(2-fluoro-4-iodophenyl)benzene1,2-diamine (0.182 mmole) was reacted with 2-methyl-5-(trifluoromethyl)furan-3-sulfonyI chloride (0.5 mmole) to form N-(3,4-difluoro~2-(2-fluoro-4-iodophenylamino)phenyl)-258

WO 2007/014011

PCT/US2006/028326 methyl-5-(trifluoromethyl)furan-3-sulfonamide. ’HNMR (CDC13) δ 2.2 (s, 3H), 5.3 (s, 1H), 6.0 (dt, 1H), 6.8 (s, 1H), 6.95 (s, 1H), 7.0-7.3 (m, 3H), 7.4 (dd, 1H).

Example 19

N-(5-(N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)sulfamoyl)methyIthiazoI-2-yl)acetamide:

HN

F

According to the general procedure 5,6-difluoro-Nl-(2-fluoro-4-iodophenyl)benzene1,2-diamine (0.182 mmole) was reacted with 2-acetamido-4-methylthiazole-5-sulfonyl chloride (0.5 mmole) to obtain N-(5-(N-(3,4-difluoro-2-(2-fluoro-4iodophenylamino)phenyl)sulfamoyl)-4-methylthiazol-2-yl)acetamide . ’HNMR(CDCl3)) δ 2.1 (s, 3H), 2.2 (s, 3H), 5.9 (dt, 1H), 6.05 (s, 1H), 7.0-7.6 (m, 3H), 7.4 (dd, 1H), 8.0 (s, 1H).

Example 20

5-(5-Chloro-l,2,4-thiadiazol-3-yI)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino) phenyl) thiophene-2-suIfonamide:

WO 2007/014011

PCT/US2006/028326

According to the general procedure 5,6-difluoro-Nl-(2-fluoro-4-iodophenyl)benzene1,2-diamine (0.182 mmole) was reacted with 5-(5-chloro-l,2,4-thiadiazol-3-yl)thiophene-2sulfonyl chloride (0.5 mmole) to obtain 5-(5-chloro-l,2,4-thiadiazol-3-yl)-N-(3,4-difluoro-25 (2-fluoro-4-iodophenylamino)phenyl)thiophene-2-sulfonamide. 'H NMR (300 MHz, CDC13)) δ 5.8 (dt, 1H), 5.95 (s, 1H), 6.95 (d, 1H),7.4 (m, 2H), 7.6 (d, 1H), 7.8 (s, 1H).

Example 21

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-3,5dimethylisoxazole-410 sulfonamide:

According to the general procedure 5,6-difluoro-Nl-(2-fluoro-4-iodophenyl) benzene· 15 1,2-diamine (0.182 mmole) was reacted with 3,5-dimethylisoxazole-4-sulfonyl chloride (0.5 mmole) to obtain N-(3,4-difluoro-2-(2-fluoro-4-iodophenyl amino)phenyl)3,5dimethylisoxazole-4-sulfonamide. ]H NMR (300 MHz, CDC13)) δ 2.2 (s, 3H), 2.4 (s, 3H),

5.8 (s, 1H), 6.0 (dt, 1H), 5.95 (s, 1H), 6.9 (s, 1H),7.O (q, 1H), 7.2 (m, 3H), 7.4 (dd, 1H).

Example 22

5-Chloro-N-(3,4-difIuoro-2-(2-fluoro-4-iodophenylamino)phenyI)-l,3-dimethyllH-pyrazole-4-sulfonamide:

WO 2007/014011

PCT/US2006/028326

According to the general procedure 5,6-difluoro-Nl-(2-fluoro-4-iodophenyl) benzene

1,2-diamine (0.182 mmole) was reacted with 5-chloro-1,3-dimethyl-lH-pyrazole-4-sulfonyl chloride (0.5 mmole) to obtain 5-chloro-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino) phenyl)-l,3-dimethyl-lH-pyrazole-4-sulfonamide. 'H NMR (300 MHz, CDC13)) δ 2.1 (s, 3H), 3.6 (s, 3H), 5.8 (s, 1H), 5.95 (dt, 1H), 7.0 (q, 1H), 7.2 (d, 1H),7.3 (m, 2H), 7.4 (dd, 1H).

Example 23

N-(3,4-difluoro-2-(2-fluoro-4-iodophenyIamino)phenyl)-2,5-dimethylfuran-310 sulfonamide:

According to the general procedure 5,6-difluoro-Nl-(2-fluoro-4-iodophenyl) benzene 15 1,2-diamine (0.182 mmole) was reacted with 2,5-dimethylfuran-3-sulfonyl chloride (0.5 mmole) to obtain N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino) phenyl)-2,5dimethylfuran-3-sulfonamide. ]H NMR (300 MHz, CDC13)) δ 2.2 (s, 3H), 2.3 (s, 3H), 5.8 (s, 1H), 6.0 (dt, 1H), 6.8 (s, 1H), 7.0 (q, 1H), 7.2 (d, 1H),7.3 (m, 2H), 7.4 (dd, 1H).

Example 24

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-l-methyi-3(trifluoromethyI)-lH-pyrazoIe-4-sulfonamide:

WO 2007/014011

PCT/US2006/028326

According to the general procedure 5,6-difluoro-Nl-(2-fluoro-4-iodophenyl) benzene1,2-diamine (0.182 mmole) was reacted with l-methyl-3-(trifluoromethyl)-lH-pyrazole-4sulfonyl chloride (0.5 mmole) to obtain N-(3,4-difluoro-2-(2-fluoro-45 iodophenylamino)phenyl)-l-methyl-3-(trifluoromethyl)-lH-pyrazole-4-sulfonamide. ’H NMR (300 MHz, CDC13)) δ 3.8 (s, 3H), 5.7 (s, 1H), 6.0 (dt, 1H), 7.0 (q, 1H), 7.2 (m, 2H), 7.4 (dd, 1H),7.8 (s, 1H).

Example 25

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)plienyI)-2,4-dimethylthiazole-5sulfonamide:

According to the general procedure 5,6-difluoro-Nl-(2-fluoro-4-iodophenyl) benzene1, 2-diamine (0.182 mmole) was reacted with 2,4-dimethylthiazole-5-sulfonyl chloride (0.5 mmole) to obtain N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-2,4dimethylthiazole-5-sulfonamide. ’H NMR (300 MHz, CDC13)) δ 2.3 (s, 3H), 2.6 (s, 3H), 5.7 (s, 1H), 5.9 (dt, 1H), 7.1 (q, 1H), 7.2 (d, 1H), 7.3 (m, 1H),7.4 (d, 1H), 7.4 (s, 1H).

Example 26

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-l,2-dimethyl-lH-imidazole-4sulfonamide:

WO 2007/014011

PCT/US2006/028326

According to the general procedure B, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzene-l,2-diamine was reacted with l,2-dimethyl-lH-imidazole-4-sulfonyl chloride to obtain the title compound. ’H NMR (300 MHz, CDCI3): δ 7.95 (br s, 1H), 7.37 (dd, 7= 1.8 & 10.8 Hz, 1H), 7.32-7.14 (m, 3H), 6.98 (dd, J= 9.6 & 17.7 Hz, 1H), 5.87 (dt, J = 4.2, 9.0 & 17.4 Hz, 1H), 5.55 (br s, 1H), 3.49 (s, 3H), 2.31 (s, 3H).

Example 27

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)thiophene-3-sulfonamide:

According to the general procedure B, 5,6-difluoro-Nl-(2-fluoro-4-iodophenyl) benzene- 1,2-diamine was reacted with thiophene-3-sulfonyl chloride to obtain the title compound. 'H NMR (300 MHz, CDC13): δ 8.00 (dd, 7= 1.2 & 3.3 Hz, 1H), 7.45 (dd, 7= 0.9 & 5.1 Hz, 1H), 7.35 (m, 2H), 7.27 (m, 2H), 6.91 (dd, 7= 9.3 & 17.1 Hz, 1H), 6.64 (ddd, 7=

2.1,4.8 & 8.7 Hz, 1H), 6.34 (dt, 7= 5.4, 8.7 & 14.1 Hz, 1H), 5.98 (br d, 7= 2.1 Hz, D2O exchangeable, 1H).

Example 28

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)furan-2-suIfonamide:

WO 2007/014011

PCT/US2006/028326

According to the general procedure B, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzene-l,2-diamine was reacted with furan-2-suIfonyl chloride to obtain the title compound. 'H NMR (300 MHz, CDC13): δ 7.53 (br s, D2O exchangeable, 1H), 7.38 (dd, J=

1.8 & 10.5 Hz, 1H), 7.30 (d, J= 8.4 Hz, 1H), 7.21 (d, J= 3.0 Hz, 1H), 6.96 (dd, J= 8.7 &

16.5 Hz, 1H), 6.87 (ddd, J= 1.8,5.1 & 9.0 Hz, 1H), 6.53 (dd, J= 1.8 & 3.6 Hz, 1H), 6.44 (dt, J= 5.1, 8.7 & 13.8 Hz, 1H), 6.22 (br s, D2O exchangeable, 1H).

Example 29

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-5-methyltInophene-2sulfonamide:

According to the general procedure B, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzene-l,2-diamine was reacted with 5-methylthiophene-2-sulfonyl chloride to obtain the title compound. 'H NMR (300 MHz, CDC13): δ 7.34 (dd, J= 0.9 & 10.2 Hz, 1H), 7.30 (ddd, J= 2.1, 4.8 & 9.0 Hz, 1H), 7.25 (d, J= 3.9 Hz, 1H), 7.07 (m, 2H), 6.65 (dd, J=

1.2 & 3.9 Hz, 1H), 5.89 (dt, J= 2.4, 8.7 & 17.4 Hz, 1H), 5.54 (br s, D2O exchangeable, 1H),

2.46 (s, 3H).

Example 30

5-ChIoro-N-(3,4-difIuoro-2-(2-fluoro-4-iodophenyIamino)phenyI)thiophene-225 sulfonamide:

WO 2007/014011

PCT/US2006/028326

According to the general procedure B, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzenel,2-diamine was reacted with 5-chlorothiophene-2-sulfonyl chloride to obtain the title compound. lH NMR (300 MHz, CDC13): δ 7.38 (dd, /= 1.5 & 10.2 Hz, 1H), 7.32 (ddd, J= 2.1, 5.1 & 9.3 Hz, 1H), 7.25 (d, J= 3.9 Hz, 1H), 7.10 (dd, J= 9.0 & 18.6 Hz, 3H), 6.84 (d, J= 4.2 Hz, 1H), 5.86 (dt, J= 1.8, 8.7 & 17.4 Hz, 1H), 5.49 (br s, D2O exchangeable, 1H).

Example 31

5-Bromo-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyI)thiophene-2sulfonamide:

According to the general procedure B, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzenel,2-diamine was reacted with 5-bromothiophene-2-sulfonyl chloride to obtain the title compound. 'H NMR (300 MHz, CDC13): δ 7.39-7.29 (m, 2H), 7.20-7.05 (m, 3H), 6.96 (d, /= 3.6 Hz, 1H), 5.85(dt, /= 2.1, 9.0 & 17.4 Hz, 1H), 5.54 (br s, 1H).

Example 32

4-Bromo-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)thiophene-3sulfonamide:

WO 2007/014011

PCT/US2006/028326

According to the general procedure B, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzenel,2-diamine was reacted with 4-bromothiophene-3-sulfonyl chloride to obtain the title compound. 'HNMR. (300 MHz, CDC13): δ 7.48 (br m, 2H), 7.39 (dd, J= 1.8 Sc 10.5 Hz, 1H), 7.28 (ddd, 7= 2.4,4.8 & 9.0 Hz, 1H), 7.17 (d, J= 8.4 Hz, 1H), 7.02 (m, 1H), 6.02 (dt, 7= 2.4, 8.7 & 17.4 Hz, 1H), 5.68 (br s, 1H).

Example 33

4-Bromo-5-chloro-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)thiophene-2sulfonamide.

According to the general procedure B, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzenel,2-diamine was reacted with 4-bromo-5-chlorothiophene-2-sulfonyl chloride to obtain the title compound. *H NMR (300 MHz, CDCI3): δ 7.42-7.34 (m, 2H), 7.25 (br m, 3H), 7.13 (dd, 7= 9.0 Sc 17.1 Hz, 1H), 6.02 (dt, 7= 2.4, 6.6 Sc ΪΊΑ Hz, 1H), 5.52 (br s, 1H).

Example 34

3-Bromo-5-chloro-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino) phenyl)thiophene-2sulfonamide:

WO 2007/014011

PCT/US2006/028326

According to the general procedure B, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzenel,2-diamine was reacted with 3-bromo-5-chlorothiophene-2-suIfonyl chloride to obtain the title compound. *H NMR (300 MHz, CDCI3): δ 7.41 (dd, 7= 2.1 & 10.5 Hz, 1H), 7.35 (br m, 2H), 7.31 (dd, 7= 2.1 & 4.2 Hz, 1H), 7.19 (d, 7= 8.7 Hz, 1H), 7.08 (dd, 7= 9.0 Sc 17.4 Hz, 1H), 6.02(dt, 7= 2.1, 8.4 & 17.1 Hz, 1H), 5.59 (br s, 1H).

Example 35

N-(3,4-difluoro-2-(2-fluoro-4-iodophenyIamino)phenyI)-2,5-dimethylthiophene-3sulfonamide:

According to the general procedure B, 5,6-difluoro-Nl-(2-fluoro~4iodophenyl)benzenel,2-diamine was reacted with 2,5-dimethylthiophene-3-sulfonyl chloride to obtain the title compound. ]H NMR (300 MHz, CDCI3): δ 7.39 (dd, 7= 1.8 & 10.2 Hz, 1H), 7.24-7.16 (br m, 2H), 7.13 (dd, 7= 9.0 8c ΠΑ Hz, 1H), 6.77 (d, 7= 9.6 Hz, 1H), 5.98 (dt, 7= 2.4, 8.7 & 17.4 Hz, 1H), 5.55 (br s, 1H), 2.33 (s, 6H).

Example 36

2,5-DichIoro-N-(3,4-difluoro-2-(2-fluoro-4-iodophenyIamino)phenyl)thiophene-3sulfonamide:

WO 2007/014011

PCT/US2006/028326

According to the general procedure B, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzene 1,2-diamine was reacted with 2,5-dichlorothiophene-3-sulfonyl chloride to obtain the title compound. *H NMR (300 MHz, CDC13): δ 7.41(dd, /= 1.5 & 10.5 Hz, 1H), 7.28-7.20 (m, 2H), 7.08 (dd, /= 9.0 & 17.4 Hz, 2H), 6.99 (s, 1H), 6.03 (dt, /= 2.1, 8.7 &

17.4 Hz, 1H), 5.56 (br s, 1H).

Example 37

Methyl 3-(N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl) sulfamoyl) thiophene2-carboxylate:

According to the general procedure B, 5,6-difluoro-N 1 -(2-fluoro-4-iodophenyl) benzene 1,2-diamine was reacted with methyl 3-(chlorosulfonyl)thiophene-2-carboxylate to obtain the title compound. ’H NMR (300 MHz, CDCI3): δ 8.58 (s, 1H), 7.43 (dd, /= 5.1 &

10.8 Hz, 2H), 7.35 (dd,/= 1.8 & 10.2 Hz, 1H), 7.31 (ddd,/= 2.1, 4.2 & 9.3 Hz, 1H), 7.04 (m, 2H), 5.88 (dt, /= 2.7, 8.7 & 17.4 Hz, 1H), 5.65 (br s, 1H), 3.85 (s, 3H).

Example 38

Methyl 5-(N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)suIfamoyl)-l-methyIlH-pyrrole-2-carboxylate:

WO 2007/014011

PCT/US2006/028326

According to the general procedure B, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzenel,2-diamine was reacted with methyl 5-(chlorosulfonyl)-l-methyl-1H5 pyrrole-2-carboxylate to obtain the title compound. !H NMR (300 MHz, CDC13): δ 7.37 (dd,

J= 1.8 & 10.5 Hz, 1H), 7.29 (m, 2H), 7.12-6.94 (m, 4H), 5.87 (dt, J= 1.8, 8.4 & 17.4 Hz, 1H), 5.56 (br s, 1H), 3.65 (s, 3H), 3.75 (s, 3H).

Example 39

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-5-methyIisoxazole-4sulfonamide:

According to the general procedure A, 5,6-difluoro-Nl-(2-fluoro-4-iodophenyl)benzenel,2diamine was reacted with the corresponding sulfonyl chloride to obtain the title compound. Yield: 22%. m/z = 508 [M-l]'.

Example 40

3-ChIoro-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)propane-lsulfonamide:

WO 2007/014011

PCT/US2006/028326

According to the general procedure A, 5,6-difluoro-Nl-(2-fluoro-4iodophenyl)benzene-1,2-diamine was reacted with 3-chloropropane-l-sulfonyl chloride to obtain the desired product. ’H NMR (500 MHz, CDCI3): δ = 7.39-7.38 (d, 1H), 7.35-7.34 (m,

1H), 7.27-7.26 (m, 1H), 7.10-7.0 (q, 1H), 6.63 (s, 1H, br), 6.15-6.11 (q, 1H), 5.60 (s, 1H, br), 3.60-3.56 (t, 2H), 3.22-3.20 (m, 2H), 2.22-2.16 (m, 2H).

General procedure C: Synthesis of N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)2-(alkylamino)ethanesulfonamide:

2-Chloro-ethanesulfonyl chloride (0.1 ml, 1 mmol) was added to a solution of 5,6difluoro-A1-(2-fluoro-4-iodophenyl)benzene- 1,2-diamine (0.364 g, 1 mmol) and triethylamine (0.28 ml, 2 mmol) in CH2CI2 (5 ml) and the reaction mixture was stirred at room temperature for 16h. Then it’s treated with an excess amine (10 eq) either in solution or as a neat liquid. The reaction mixture stirred at room temperature for additional 6h. The reaction mixture diluted with CH2CI2 (10 ml) and water (10 ml). The organic layer was sequentially washed with dil. HCI (2x20 ml, 2N) and saturated NaHCO3 (2x10 ml) solution. Then the CH2CI2 layer dried (MgSO4) and evaporated to obtain the crude product. The impure product was purified under preparative HPLC conditions to obtain the pure products in 50-60 % yield.

Example 41

N-(2-(4-chloro-2-fluorophenylamino)-3,4-difluorophenyl) cyclopropanesulfonamide:

See example 1. 'HNMR (300 MHz, CDC13) δ 0.85-0.95 (m, 2H), 1.05-1.15 (m, 2H),

2.2-2.4 (m, 1H), 5.8 (s, 1H), 6.3 (t, 1H), 6.6-7.4 (m, 5H); mfz = 375 [M-1]'.

Example 42

N-(3,4-difluoro-2-(4-iodo-2-methylphenylamino)phenyl)cyclopropanesulfonamide:

WO 2007/014011

PCT/US2006/028326

See example 1. 'HNMR (CDCb) δ 0.80-1.0 (m, 2H), 1.05-1.20 (m, 2H), 1.55 (s, 3H), 2.4-2.5 (m, 1H), 5.6 (s, 1H), 6.2 (dd, 1H), 6.4 (s, 1H), 7.1 (q, 1H). 7.3-7.4 (m, 2H), 7.5 (s,

1H); w/z = 463 [M-l]’.

Example 43

N-(2-(4-tert-butyl-2-chlorophenylamino)-3,4-difluorophenyl) cyclopropanesulfonamide:

See example 1. ’H NMR (300 MHz, CDC13) δ 0.9-1.0 (m, 2H), 1.05-1.20 (m, 2H), 1.3 (s, 9H), 2.4-2.5 (m, 1H), 5.8 (s, 1H), 6.3 (dd, 1H), 6.6 (s, 1H), 7.0-7.2 (m, 2H), 7.3-7.4 (m, 2H); m/z = 413 [M-l]’.

Example 44

N-(2-(2,4-dichlorophenylamino)-3,4-difluorophenyl)cyclopropanesuIfonamide:

WO 2007/014011

PCT/US2006/028326

See example 1. 'H NMR (300 MHz, CDC13) δ 0.9-1.0 (m, 2H), 1.05-1.20 (m, 2H), 2.4-2.5 (m, 1H), 6.0 (s, 1H), 6.3 (dd, 1H), 6.6 (s, 1H), 7.0-7.2 (m, 2H), 7.3-7.4 (m, 2H); m/z = 392 [M-l]’.

Example 45

3-Chloro-N-(3,4-difluoro-2-(2-fluoro-4-trifluoromethyI) phenylamino)phenyl)propane1-sulfonamide:

See example 1. NMR (300 MHz, CDC13): δ 7.39-7.26 (m, 2H), 7.25 (m, 1H), 7.18 (dd, 7= 9.0 & 17.7 Hz, 1H), 6.78 (br s, D2O exchangeable, 1H), 6.50 (t, J= 8.1 Hz, 1H), 6.00 (br d, D2O exchangeable, 7= 1.5 Hz, 1H), 3.63 (t, 7= 6.0 & 6.3 Hz, 2H), 3.29 (t, 7= 7.2 &

7.8 Hz, 2H), 2.26 (quintet, 2H); m/z = 445 [M-l].

Example 46

N-(3,4-difluoro-2-(2-chloro-4-trifluoromethyl)phenylamino)methanesulfonamide:

See example 1. !H NMR (300 MHz, CDC13): δ 7.65 (d, 7=7.8 Hz, 1H), 7.33 (m, 2H), 7.19 (dd, 7= 9.3 & 17.4 Hz, 1H), 6.90 (br s, D2O exchangeable, 1H), 6.45 (dd, 7= 1.5 & 8.4 Hz, 1H), 6.39 (br s, D2O exchangeable, 1H), 3.02 (s, 3H); m/z = 399 [M-l]’.

Example 47

WO 2007/014011

PCT/US2006/028326

3-Chloro-N-(3,4-difluoro-2-(2-chloro-4-trifluoromethyI) phenylamino)phenyl)propane1-sulfonamide:

See example 1. 'H NMR (300 MHz, CDC13): δ 7.66 (d, J= 1.5 Hz, 1H), 7.36 (m, 2H), 7.19 (dd, 7= 9.0 & 17.4 Hz, 1H), 6.91 (br s, D2O exchangeable, 1H), 6.50 (dd, J= 8.4 & 1.5 Hz, 1H), 6.37 (s, D2O exchangeable, 1H), 3.62 (t, 7= 6.0 Hz, 2H), 3.29 (t, 7= 7.5 & 7.8 Hz, 2H), 2.27 (quintet, 2H); m/z = 462 [M-l]'.

Example 48

3-Chloro-N-(3,4-difluoro-2-(2-bromo-4-trifluoromethyl) phenylamino)phenyl)propane1-sulfonamide:

See example 1. ’H NMR (300 MHz, CDC13): δ 7.82 (s, 1H), 7.38 (m, 2H), 7.20 (dd, 7 = 9.0 & 17.7 Hz, 1H), 6.62 (br s, D2O exchangeable, 1H), 6.43 (d, 7= 8.4 Hz, 1H), 6.23 (s, D2O exchangeable, 1H), 3.65 (t, 7= 6.0 Hz, 2H), 3.30 (t, 7= 7.5 Hz, 2H), 2.28 (quintet, 2H);

zn/z = 506 [M-l]'.

Example 49

Cyclopropanesulfonic acid (3,4,6-trifluoro-2-(2-fluoro-4-iodo-phenyIanrino)-phenyl)amide:

Step A (2-Fluoro-4-iodo-phenvl)-(2,3,5-trifluoro-6-nitro-phenyr)-amine:

WO 2007/014011

PCT/US2006/028326

A stirred solution of 2-fluoro-4-iodoaniline (3.64 gm, 15.37 mmol) in dry THF (100 ml) under nitrogen was cooled to -78°C and a solution of 1.0 M lithium hexa methyl disilazide (LiN(SiMe3)2) “LHMDS” (15.37 ml, 15.37 mmol) was added slowly. This reaction mixture was kept stirring at -78°C for another hour and then 2,3,4,6-tetrafluoronitrobenzene was added. The reaction mixture was allowed to warm to room temperature and stirring continued for another 16 hours. Ethyl acetate (200 ml) was added to the reaction mixture and was washed with water. Organic layer was dried over sodium sulfate and further purified by column chromatography to provide yellow solid (3.75 gm, yield: 59.24%). M-H1: 410.9. *H NMR (DMSO, 300 MHz): 6.85 (t, 1H); 7.38 (d, 1H); 7.62 (m, 2H); 8.78 (s, 1H).

Step B 3A6-Trifluoro-N2-f2-Fluoro-4-iodo-phenvl)-benzene-l,2-diamine:

To the stirred solution of (2-fluoro-4-iodo-phenyl)-(2,3,5-trifluoro-6-nitro-phenyl)amine 3 (5.2 gm, 12.62 mmol) in EtOH (200 ml), ammonium chloride (10.12 gm, 189.3 mmol) and iron powder (10.57 gm, 189.3 mmol) was added. This reaction mixture was kept stirring at reflux for 16 hours. Reaction mixture was allowed to cool and was filtered over celite and concentrated to dryness. The residue obtained was taken into EtOAc and was washed with water. The EtOAc layer was dried over sodium sulfate and further purified by crystallization from EtOH to provide off-white solid (3.2 gm, yield: 66.39%). M-H+: 381.1.

Ή NMR (DMSO, 300 MHz): 5.0 (s, 2H); 6.2 (t, 1H); 7,2 - 7.3 (m, 2H); 7.45 (s, 1H); 7.5 (d,

1H).

WO 2007/014011

PCT/US2006/028326

Step C: 4,6,7-Trifluoro-1 -(2-Fluoro-4-iodo-phenyl)-1,3 ,-dihvdrobenzoimidazole-2one:

F

F

To the stirred solution of 3,4,6-trifluoro-N2-(2-Fluoro-4-iodo-phenyl)-benzene-l,2diamine 3 (0.285 gm, 0.74 mmol) in CH2CI2 (2 ml), Ι,Γ-carbonyldiimidazole (0.125 gm, 0.75 mmol) was added. This reaction mixture was kept stirring at room temperature for 16 hours when product precipitated out. The white solid was filtered and used further without any purification. (0.2 gm, yield: 65.85%); m/z = 407 [M-l]'.

Step D/E: Cyclopropanesulfonic acid (3,4.6-trifluoro-2-(2-fluoro-4-iodophenylaminoI-phenvD-amide:

F

A stirred solution of 4,6,7-trifluoro-l-(2-fluoro-4-iodo-phenyl)-l,3,dihydrobenzimidazol-2-one (0.2 gm, 0.41 mmol) in dry THF (4 ml) under nitrogen was cooled to -78°C and a solution of 1.0 M LiHMDS (0.41 ml, 0.41 mmol) was added slowly. (2 ml) followed by addition of cyclopropanesulfonyl chloride (0.050 ml, 0.49 mmol). This reaction mixture was kept stirring at room temperature for 16 hours, concentrated to dryness and was taken into EtOAc. The EtOAc was washed with water, dried over sodium sulfate and concentrated to dryness. The residue obtained l-cyclopropanesulfonyl-4,5,7-trifluoro-3-(2fluoro-4-iodo-phenyl)-l,3-dihydro-benzimidazoI-2-one 5 was taken into dioxane (2 ml) and to this 1.0 N NaOH (0.5ml) was added and kept stirring at room 50°C for 16 hours. TLC indicated incomplete reaction, the product was purified by HPLC to provide off-white solid

WO 2007/014011

PCT/US2006/028326

1.2 (m, 2H); 2.45-2.55 (m, 1H); 6.05 (s, 1H); 6.44 - 6.54 (m, 1 H); 7.1 (s, 1H); 7.4 - 7.7 (d, 1H); 7.38 - 7.44 (dd, 1H); mb = 485 [M-l]’.

Example 50 5

N-(3,4-difIuoro-2-(4-fluoro-2-iodophenylamino)-6-ethoxyphenyl) cyclopropane sulfonamide:

Step A: (2,3-Difluoro-5-methoxv-6-nitro-phenvl)-(2-fluoro-4-iodo-phenvl)-amine:

A stirred solution of (2-fluoro-4-iodo-phenyI)-(2,3,5-trifluoro-6-nitro-phenyl)-amine (1.23 gm, 3 mmol) in dry THF (25 ml) under nitrogen was cooled to -78°C and a solution of

25% NaOMe (0.68 ml, 0.3 mmol) was added slowly. Reaction mixture was allowed to warm to room temperature and stirring continued for another 16 hours. TLC indicated incomplete reaction. Ethyl acetate (100 ml) was added to the reaction mixture and was washed with water. Organic layer was dried over sodium sulfate and further purified by column chromatography to provide yellow solid (0.6 gm, yield: 47.6%). m/z = 424 [M=H]+.

Step B: 5,6-Difluoro-Nl-(4-fluoro-2-iodophenvD-3-methoxybenzene“E2-diamme:

To the stirred solution of (2,3-difIuoro-5-methoxy-6-nitro-phenyl)-(2-fluoro-4-iodophenyl)-amine (0.57 gm, 1.34 mmol) in EtOH (20 ml), ammonium chloride (1.18 gm, 20.16 mmol) and iron powder (1.15 gm, 21.44 mmol) was added. This reaction mixture was kept stirring at reflux for 16 hours. Reaction mixture was allowed to cool and was filtered over

WO 2007/014011

PCT/US2006/028326 celite and concentrated to dryness. The residue obtained was taken into EtOAc and was washed with water. The EtOAc layer was dried over sodium sulfate and further purified by crystallization from EtOH to provide off-white solid (0.47 gm, yield: 90.3%). M-H+: 393.2. ’H NMR (DMSO, 300 MHz): 3.76 (s, 3H); 6.1 (t, 1H); 6.8 - 7.0 (m, 1H); 7.2 (d, 1H); 7.35 (s,

1H); 7.42 (d, 1H).

Step C: 6,7-Difluoro-1 -f 4-fluoro-2-iodophenvl)-4-methoxy-1 H-benzo [di imidazol2(3H)-one:

To the stirred solution of 5,6-difluoro-Nl-(4-fluoro-2-iodophenyl)-3methoxybenzene-1,2-diamine (0.17 gm, 0.43 mmol) in CH2CI2 (2 ml), 1,1’Carbonyldiimidazole (0.085 gm, 0.53 mmol) was added. This reaction mixture was kept stirring at room temperature for 16 hours when product precipitated out. The white solid was filtered and used further without any purification. (0.089 gm); m/z = 419 [M-l]'.

Step D/F: N-('3,4-difluoro-2-(4-fluoro-2-iodophenvlamino,)-6-methoxvphenvr) cyclopropanesulfonamide:

A stirred solution of l-(cyclopropylsulfonyl)-4,5-difluoro-3-(2-fluoro-4-iodophenyl)7-methoxy-lH-benzo[d]imidazol-2(3H)-one (0.89 gm, 0.17 mmol) in dry THF (4 ml) under nitrogen was cooled to -78°C and a solution of 1.0 M LiHMDS (0.17 ml, 0.17 mmol) was added slowly. (2 ml) followed by addition of Cyclopropanesulfonyl chloride (0.021 ml, 0.21 mmol). This reaction mixture was kept stirring at room temperature for 16 hours,

WO 2007/014011

PCT/US2006/028326 concentrated to dryness and was taken into EtOAc. The EtOAc was washed with water, dried over sodium sulfate and concentrated to dryness. The resulting l-(cyclopropylsulfonyl)-4,5difluoro-3-(2-fluoro-4-iodophenyl)-7-methoxy-lH-benzo[d]imidazol-2(3H)-one was taken into dioxane (2 ml) and to this 1.0 N NaOH (0.5ml) was added and kept stirring at room 50°C for 16 hours. TLC indicated incomplete reaction, the product was purified by HPLC to provide off-white solid (2.5 mg) M+H*: 484.7, M-H*: 497.3. ]H NMR (CDC13j 300 MHz): 0.85-0.95 (m, 2H); 1.05 - 1.15 (m, 2H); 2.4-2.5 (m, 1H); 3.9 (s, 3H); 6.1 (s, 1H); 6.4-6.6 (m, 2 H); 7.3 (m, 1H); 7.35 - 7.4 (dd, 1H); m/z = 497 [M-l]’.

Example 51

Methylsulfonic acid (3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-6-methoxy-phenyl)arnide:

A stirred solution of 5,6-difluoro-Nl-(4-fluoro-2-iodophenyl)-3-methoxybenzene-l,2diamine (0.150 gm, 0.38 mmol) in dry CH2CI2 (4 ml), TEA (.264 ml, 1.9 mmol) and Methanesulfonyl chloride was added slowly. This reaction mixture was kept stirring at room temperature for 16 hours, TLC indicated incomplete reaction along with starting material two products were observed. The reaction mixture was washed with water, organic layer was dried over sodium sulfate and concentrated to dryness, the product was purified by column chromatography. The minor product was found to be the expected compound (6.4 mg). ΜΗ*: 471.5. 'H NMR (CDC13,300 MHz): 3.9 (s, 3H); 6.05 (s, 1H); 6.4 - 6.5 (m, 1 H); 6.5 - 6.6 (m, 1H); 7.2 (s, lH);7.28(d, 1H); 7.35 - 7.4 (d, 1H); /n/z = 471 [M-l]’.

Example 52

1-(2,3-Dihydroxy-propyl)-cyclopropanesuIfonic acid [3,4,6-trifluoro-2-(4-fluoro-2-iodophenylamino)-phenyl]-amide:

WO 2007/014011

PCT/US2006/028326

Step A: 1 -Allyl-cyclopropanesulfonic acid Γ3.4.6-trifluoro-2-f2-fluoro-4-iodophenylamino)-phenyl'|-amide.·

According to the general procedure B, 1-allyl-cyclopropanesulfonyl chloride was reacted with 3,5,6-trifluoro-N1-(2-fluoro-4-iodophenyl)benzene-l,2-diamine to obtain the title product. *H NMR (CDCfe, 300 MHz): δ 7.41 (dd, 1H), 7.38 (dd, 1H), 7.09 (s, 1H), 6.78 (m, 1H), 6.49 (m, 1H), 5.96 (s, 1H), 5.86 (m, 1H), 5.18 (d, 2H), 2.76 (d, 2H), 1.23 (m, 2H), 0.872 (m, 2H).

Step B: l-(2.3-Dihvdroxvpropvl)-N-(3.4.6-trifluoro-2-f2-fluoro-4-iodophenvlamino') phenylkvclopropane-l-sulfonamide:

1-Allyl-cyclopropanesulfonic acid [3,4,6-trifluoro-2-(2-fluoro-4-iodo-phenyl amino)phenyl]-amide ( 110 mg, 0.21 mmole) and 4-methylmorpholine N-oxide (24.6 mg, 0.21 mmole) was dissolved in THF (8 mL). Osmium tetroxide was added at room temperature (0.021 mmole, 0.153 mL, 4% in H2O) and the reaction mixture was stirred at room temperature for 16 hours. EtOAc was added, the organic phase was washed with water, dried (MgSO4) and concentrated under reduced pressure. The residue was purified over silica gel chromatography (eluants: EtOAc/ MeOH) to obtain the titled product (0. 89 g, 75 %). ’H NMR (CDC13, 300 MHz): δ 7.39 (dd, J = 1.5 & 10.6 Hz, 1H), 7.29 (d, J = 8.8 Hz, 1H), 7.28 (s, 1H), 6.97 (s, 1H), 6.76 (m, 1H), 6.49 (m, 1H), 4.13 (m, 1H), 3.66 (dd, J = 3.7 & 11.4 Hz,

WO 2007/014011

PCT/US2006/028326

1H), 3.53 (dd. J = 6.7 & 11.2 Hz, 1H), 2.50(dd, J= 10.0 & 16.1 Hz, 1H), 1.6 (m,lH), 1.46 (m, 1H), 1.28 (m, 1H), 1.20 (m, 2H), 0.92 (m, 2H); m/z = 559 [M-l]’.

Example 53 (S)-l-(2,3-dihydroxypropyI)-N-(3,4,6-trifluoro-2-(2-fluoro-4-iodophenylamino) phenyl)cyclopropane-l-sulfonamide:

The pure S isomer was obtained by chiral HPLC separation of the racemic mixture (example 56). 'HNMR (CDC13,300 MHz): δ 7.39 (dd, J = 1.5 & 10.6 Hz, 1H), 7.29 (d, J = 8.8 Hz, 1H), 7.28 (s, 1H), 6.97 (s, 1H), 6.76 (m, 1H), 6.49 (m, 1H), 4.13 (m, 1H), 3.66 (dd, J = 3.7 & 11.4 Hz, 1H), 3.53 (dd. J= 6.7 & 11.2 Hz, 1H), 2.50(dd, J= 10.0 & 16.1 Hz, 1H), 1.6 (m,lH), 1.46 (m, 1H), 1.28 (m, 1H), 1.20 (m, 2H), 0.92 (m, 2H); m/z = 559 [M-l]’.

Example 54 (R)-l-(2,3-dihydroxypropyl)-N-(3,4,6-trifluoro-2-(2-fluoro-4-iodophenylamino) phenyl)cyclopropame-l-sulfonamide:

The pure R isomer was obtained by chiral HPLC separation of the racemic mixture (example 53). ’H NMR (CDC13, 300 MHz): δ 7.39 (dd, J = 1.5 & 10.6 Hz, 1H), 7.29 (d, J =

8.8 Hz, 1H), 7.28 (s, 1H), 6.97 (s, 1H), 6.76 (m, 1H), 6.49 (m, 1H), 4.13 (m, 1H), 3.66 (dd, J

WO 2007/014011

PCT/US2006/028326 = 3.7 & 11.4 Hz, 1H), 3.53 (dd. J = 6.7 & 11.2 Hz, 1H), 2.50(dd, J = 10.0 & 16.1 Hz, 1H), 1.6 (m,lH), 1.46 (m, 1H), 1.28 (m, 1H), 1.20 (m, 2H), 0.92 (m, 2H); m/z= 559 [M-l]'.

Example 55

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyI)-l-(2,3-dihydroxypropyl) cyclopropane-l-sulfonamide:

Step A: l-Allyl-N-O^-difluoro-Z-Gj-fluoro^-iodophenylamino)^methoxyphenvDcvclopropane-1 -sulfonamide

According to the general procedure B, l-allyl-cyclopropanesulfonyl chloride was reacted with 5,6-difluoro-Nl-(2-fiuoro-4-iodophenyl)-3-methoxybenzene-l,2-diamine to obtain the title product. ]H NMR (CDC13, 300 MHz): δ 7.417 (dd, 1H), 7.309(s, 1H), 7.25 (m, 1H), 6.89 (m, 1H), 6.52(m, 1H), 6.427 (m, 1H), 6.03 (s,lH), 5.668 (m, 1H), 5.11 (t, 1H), 3.9 (s, 3H), 2.75 (d, 2H), 1.21 (m, 2H), 0.767 (m, 2H).

Step B: N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-l-(2,3dihydroxypropyl) cyclopropane-l-sulfonamide

l-AHyl-N-(3,4-difluoro-2-(2-fluoro-4-iodophenyIamino)-6-methoxyphenyl) cyclopropane-l-sulfonamide (97 mg, 0.18 mmole) and 4-methylmorpholine N-oxide (21 mg,

WO 2007/014011

PCT/US2006/028326

0.18 mmole) were dissolved in THF (8 mL). Osmium tetroxide was added at room temperature (0.018 mmole, 0.13 mL, 4% in H2O) and the reaction mixture was stirred at room temperature for 16 hours. EtOAc was added, the organic phase was washed with water, dried (MgSO4) and concentrated under reduced pressure. The residue was purified over silica gel chromatography (eluants: EtOAc/ MeOH) to obtain the titled product (0. 80 g, 78 %). 'H NMR (CDC13, 300 MHz): δ 7.38 (dd, J = 1.7 & 10.3 Ηζ,ΙΗ), 7.26 (m, 1H), 7.14 (s, 1H),

6.87 (s, 1H), 6.53 (dd, J = 6.8 & 11.4 Hz, 1H), 6.43 (m, 1H), 4.06 (m, 1H), 3.89 (s, 3H), 3.63 (dd, J = 3.7 & 11.1 Hz, 1H), 3.49 (dd, J = 6.4 & 11.1 Hz, 1H), 2.3 (dd, J = 9.7 & 16.1 Hz,

1H), 1.77 (dd, J = 1.9 & 16.0 Hz, 1H), 1.37 (m, 1H), 1.25 (m, 1H), 1.21 (m, 2H), 0.86 (m, 2H);m/z = 571 [M-l]’.

Example 56 (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenyIamino)-6-methoxyphenyI)-l-(2,3dihydroxypropyl)cyclopropane-l-sulfonamide:

The pure S isomer was obtained by chiral HPLC separation of the racemic mixture (example 59). Ή NMR (CDC13, 300 MHz): δ 7.38 (dd, J = 1.7 & 10.3 Ηζ,ΙΗ), 7.26 (m, 1H), 7.14 (s, 1H), 6.87 (s, 1H), 6.53 (dd, J = 6.8 & 11.4 Hz, 1H), 6.43 (m, 1H), 4.06 (m, 1H), 3.89 (s, 3H), 3.63 (dd, J = 3.7 & 11.1 Hz, 1H), 3.49 (dd, J = 6.4 & 11.1 Hz, 1H), 2.3 (dd, J = 9.7 & 16.1 Hz, 1H), 1.77 (dd, J = 1.9 & 16.0 Hz, 1H), 1.37 (m, 1H), 1.25 (m, 1H), 1.21 (m, 2H), 0.86 (m, 2H); τη/ζ= 571 [M-l]‘.

Example 57 (R)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyI)-l-(2,3dihydroxypropyl)cyclopropane-l-sulfonamide:

WO 2007/014011

PCT/US2006/028326

The pure R isomer was obtained by chiral HPLC separation of the racemic mixture (example 59). ]HNMR (CDCfe, 300 MHz): δ 7.38 (dd, J = 1.7 & 10.3 Ηζ,ΙΗ), 7.26 (m, 1H),

7.14 (s, 1H), 6.87 (s, 1H), 6.53 (dd, J = 6.8 & 11.4 Hz, 1H), 6.43 (m, 1H), 4.06 (m, 1H), 3.89 (s, 3H), 3.63 (dd, J = 3.7 & 11.1 Hz, 1H), 3.49 (dd, J = 6.4 & 11.1 Hz, 1H), 2.3 (dd, J = 9.7 & 16.1 Hz, 1H), 1.77 (dd, J = 1.9 & 16.0 Hz, 1H), 1.37 (m, 1H), 1.25 (m, 1H), 1.21 (m, 2H), 0.86 (m, 2H);w/z=571 [M-l]'.

Example 58 l-(2-hydroxyethyl)-N-(3,4,6-trifluoro-2-(2-fluoro-4-iodophenylamino)phenyl) cyclopropane-l-sulfonamide:

Step A: TBS-protected l-(2-hvdroxvethvl)-N-(3A6-trifluoro-2-(2-fluoro-4iodophenylaminolphenvD cyclopropane-1 -sulfonamide:

According to the general procedure B, the sulfonyl chloride prepared in step C of 20 example 16 was reacted with 5,6-difluoro-Nl-(2-fluoro-4-iodophenyl)-3-fluorobenzene-l,2diamine to obtain the title product. Yield: 13%. ’H-NMR (300 MHz, CDCI3): δ = 7.51 (s, 1H, br), 7.37-7.35 (d, 1H), 7.27-7.25 (d, 1H), 6.94 (s, 1H, br), 6.78-6.68 (m, 1H), 6.46-6.44 (m, 1H), 3.90-3.88 (t, 2H), 2.12-2.10 (t, 2H), 1.31-1.28 (m, 2H), 0.91-0.89 (m, 2H), 0.86 (s, 9H), 0.05 (s, 6H); m/z = 643 [M-l]'.

WO 2007/014011

PCT/US2006/028326

Step B: l-('2-hvdroxvethvl')-N-f3.4,6-trifluoro-2-f2-fluoro-4-iodophenvlaminol· phenvD cyclopropane-l-sulfonamide:

Same procedure as in step E, example 16. Yield: 100%. 'H-NMR (300 MHz, CDC13): δ = 7.51 (s, 1H, br), 7.37-7.35 (d, 1H), 7.27-7.25 (d, 1H), 6.94 (s, 1H, br), 6.78-6.68 (m, 1H),

6.46-6.44 (m, 1H), 3.90-3.88 (t, 2H), 2.12-2.10 (t, 2H), 1.31-1.28 (m, 2H), 0.91-0.89 (m, 2H);

m/z= 529 [M-l].

Example 59

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-l-(215 hydroxyethyl)cyclopropane-l-sulfonamide:

Step A: TBS-protected N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6methoxyphenyl)-1 -(2-hvdroxyethvl)cvclopropane-1 -sulfonamide:

WO 2007/014011

PCT/US2006/028326

According to the general procedure B, the sulfonyl chloride prepared in step C of example 16 was reacted with 5,6-difluoro-Nl-(2-fluoro-4-iodophenyl)-3 -methoxy-benzene1, 2-diamine to obtain the title product. Yield: 37%. ’H-NMR (300 MHz, CDCI3): δ = 7.407.34 (dd, 1H), 7.23-7.21 (m, 1H), 6.61 (s, 1H, br), 6.57-6.49 (dd, 1H), 6.48-6.39 (m, 1H), 3.9

3.7 (m, 5H), 2.15-2.05 (t, 2H), 1.30-1.20 (m, 2H), 0.95-0.80 (m, 11H), 0.05 (s, 6H); m/z =

655 [M-l]’.

Step B: N-(,3,4-difluoro-2-(2-fluoro-4-iodophenvlamino)-6-methoxyphenvn-l-(2hydroxvethyl)cyclopropane-l-sulfonamide:

Same procedure as in step E, example 16. Yield: 100%.1 H-NMR (300 MHz, CDCI3): δ = 7.40-7.34 (dd, 1H), 7.23-7.21 (m, 1H), 6.61 (s, 1H, br), 6.57-6.49 (dd, 1H), 6.48-6.39 (m,

1H), 3.9-3.7 (m, 5H), 2.15-2.05 (t, 2H), 1.30-1.20 (m, 2H), 0.95-0.80 (m, 2H); 541 [ΜΙ]’·

Example 60

N-(3,4-difluoro-2-(2-fluoro-4-iodophenyIamino)-6-methoxyphenyl)-l-(3-hydroxy-220 (hydroxymethyl)propyl)cyclopropane-l-smlfonamide:

Step A: Dimethyl 2-(2-bromoallyDmalonate:

WO 2007/014011

PCT/US2006/028326

To a suspension of sodium hydride (5.0 g, 125 mmol) in HMPA (50 ml, distilled from calcium hydride) was added a solution of dimethyl malonate (11.7 ml, 100 mmol) in HMPA (5 ml) at 0°C under argon. The mixture was heated to 50°C and stirred 1 hour. Following this the solution was again cooled to 0°C, and a solution of 2,3-dibromopropene (12.2 ml, 100 mmol) in HMPA (5 ml) was added to the reaction mixture. Next, the solution was warmed to 40°C and stirred for 1 hour. The reaction mixture was quenched with aq. HCI (10%, 88 ml) and extracted with ether (3 x 45 ml). The organic fractions were collected, dried over MgSO4, and the solvent was removed in vacuo. The crude oil was purified via silica gel chromatography (eluants: chloroform/hexane) to obtain the titled product as a colorless oil (16.3 g, 65%). 'H-NMR (300 MHz, CDC13) δ 5.70 (d, J = 1.8 Hz, 1 H), 5.48 (d, J = 1.8 Hz,

1H), 3.63 (t, J = 7.5 Hz, 1 H), 3.76 (s, 6 H), 3.04 (d, J = 7.5 Hz, 2 H).

Step B: 2-(2-Bromoallyl)propane-l,3-diol:

OH OH

Lithium aluminum hydride (1.9 g, 7.65 mmol) was slurried in anhydrous diethyl ether (50 ml) and cooled to -78°C in a dry ice/acetone bath. A solution of the product from step A (0.639 g, 16.84 mmol) in dry ether (26 ml) was then added dropwise. After the malonate was added, the solution was allowed warm to room temperature and stirring was continued for 3 hours. The reaction was quenched with brine (50 ml), extracted with ethyl acetate (3 x 25 ml) and dried over MgSO4. The solvent was removed in vacuo to give the desired product (1.3 g, 86%) which was used for the next step without further purification. 'H-NMR (300 MHz, CDC13) δ 5.66 (d, J= 1.2 Hz, 1 H), 5.48 (d, J = 1.5 Hz, 1H), 3.86 (m, 2 H), 3.73 (m, 2

H), 2.51 (d, J = 7.5 Hz, 2 H), 2.40 (br s, 2 H), 2,15 (m, 1 H).

Step C: Di-tert-butyldimethylsilyl protected 2-f2-bromoallyl)propane-L3-diol:

TBSO

WO 2007/014011

PCT/US2006/028326

The product from step B (2.8 g, 14.20 mmol) was dissolved in anhydrous THF (140 ml). Anhydrous pyridine (2.5 ml, 31.24 mmol) was added, and the solution was cooled to 0°C. tert-Butyldimethylsilyltriflate (7.2 ml, 31.24 mmol) was added dropwise, and upon completion, the reaction solution was heated to 35°C. After stirring for 6 days, the reaction was quenched with 100 ml brine, extracted with ethyl acetate (3 x 50 ml) and dried over MgSC>4. The combined organic phases were evaporated to obtain the crude product (5.5 g, 91%) as a yellow oil which was used in the next step without further purification. ’H-NMR (300 MHz, CDCb) δ 5.54 (d, J = 0.9 Hz, 1 H), 5.40 (d, J = 1.2 Hz, 1H), 3.55 (d, J = 5.4,4 H), 10 2.40 (d, J = 6.9 Hz, 2 H), 1.97 (m, 1 H), 0.85 (s, 18 H), 0.02 (s, 9 H).

Step D: Di-tert-butyldimethylsilyl protected 2-(Tl-bromocyclopropyl)roethy]) propane-1,3-diol:

TBSO

A reaction flask was charged with anhydrous CH2CI2 (10 ml) and diethyl zinc (1.0 M in hexanes, 4.65 ml, 4.65 mmol) at 0°C. Trifluoroacetic acid (0.358 ml, 4.65 mmol) was added dropwise and the solution was allowed to stir for 20 minutes. Diiodomethane (0.375 ml, 4.65 mmol) was then added and the solution was stirred for another 20 minutes. Finally, the product from step C (0.492 g, 1.16 mmol) was added and the solution was allowed to warm to ambient temperature, stirring for 16 hours. The reaction was quenched with saturated aqueous NH4CI. The layers were partitioned and the aqueous phase was extracted with chloroform (3x5 ml). The combined organic phases were washed with brine (10 ml), dried over MgSCL, and the volatiles were removed in vacuo. The resulting crude was purified via silica gel chromatography (eluants: chloroform/hexanes) to provide the product as a clear oil (0.280 g, 64%). ’H-NMR (300 MHz, CDC13) δ 3.66 (d, J = 5.4,4 H), 2.08 (m, 1

H), 1.64 (d, J = 6.9,2 H), 1.13 (m, 2 H), 0.88 (s, 18 H), 0.81 (m, 2 H), 0.04 (s, 9 H).

Step E: Di-tert-butyldimethvlsilyl protected 1-(3-hvdroxy-2-(hvdroxvmethyl)propvl) cyclopropane-1-sulfonyl chloride:

WO 2007/014011

PCT/US2006/028326

TBSO

lei

The product from step D (0.507 g, 1.16 mmol) was dissolved in anhydrous ether (6 ml) and the reaction solution was cooled to -78°C. Following this, tert-butyllithium (1.7 M in pentane, 1.50 ml, 2.55 mmol) was added dropwise over 5 minutes. After stirring for 0.5 hours, the lithiated product was transferred via cannula to a stirred solution of sulfuryl chloride (0.206 ml, 2.55 mmol) in dry ether (6 ml) at -78°C. Once the transfer is complete, the solution was allowed to warm to room temperature, the solvent was evaporated and the resulting white solid was slurried in dry hexanes. This slurry was immediately filtered through celite, and all volatiles were removed in vacuo. The resulting crude product (0.376 g, 71%) was isolated as a yellow oil and was used in the following step without further purification. 'H-NMR (300 MHz, CDC13) δ 3.60 (m, 4 H), 2.16 (m, 1 H), 2.03 (d, 2 H), 0.88 (s, 18H),0.04(s,9H).

Step F: Di-tert-butyldimethylsilvl protected N-(3,4-difluoro-2-(2-fluoro-4iodophenvlamino)-6-methoxvphenvl)-l-(3-hvdroxy-2-(hvdroxvmethvl)propyl) cyclopropane1-sulfonamide:

TBS.

ZTBS

O O

5,6-difluoro-Nl-(2-fluoro-4-iodophenyl)-3-methoxybenzene-l,2-diamine (8.8 mg, 0.022 mmol) was dissolved in anhydrous pyridine (0.5 ml) under an argon atmosphere. The product from step E (20.5 mg, 0.045 mmol), dissolved in dry pyridine (0.5 ml), was added to the reaction flask and the mixture was heated at 80°C for 21 hours. The solvent was removed

WO 2007/014011

PCT/US2006/028326 in vacuo and the resulting crude was purified via silica gel chromatography (eluents: ethyl acetate/hexanes) to provide the title compound (2.75 mg, 15%). m/z 813.5 (M-l).

Step G: N-(3,4-difluoro-2-(2-fluoro-4-iodophenvlamino)-6-methoxvphenyl)-l-(35 hvdroxy-2-(hvdroxymethvl)propyl)cyclopropane-l-sulfonamide:

The product from step F (27.9 mg, 0.0342 mmol) was dissolved in THF (1 ml) and 10 treated with aqueous HC1 (1.2 N, 0.2 ml) at 0°C. The resulting solution was stirred for 4 hours. Following this, the reaction was quenched with saturated aqueous NaHCO3, extracted with ethyl acetate, dried over MgSO4 and the volatiles were removed in vacuo. The resulting crude was purified via silica gel chromatography (eluents: methanol/chloroform) followed by LC-MS purification to provide the title compound (11.8 mg, 59%). ’H-NMR (300 MHz,

CD3OD) δ 7.32 (dd, 1 H), 7.21 (d, 1 H), 6.76 (dd, 1 H), 6.33 (m, 1 H), 3.82 (s, 3 H), 3.52 (d, 4 H), 2.01 (m, 1 H), 1.88 (d, 2 H), 1.07 (m, 2 H), 0.75 (m, 2 H), m/z 585.3 (M-l).

Example 61

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyI) cyclobutane 20 sulfonamide:

Step A: Cyclobutanesulfonvl chloride:

so2ci

To a suspension of Mg turnings (0.790 g, 32.5 mmol) in 20 ml anhydrous diethyl ether was added a solution of cyclobutylbromide (1.8 ml, 2.5722 g, 19.1 mmol) in 20 ml

WO 2007/014011

PCT/US2006/028326 diethyl ether in small portions with strong stirring. After the initial exothermic reaction had ceased, the mixture was further heated to the reflux temperature for 30 min. The suspension was cooled down to room temperature and the supernatant was added in small portions to an ice-cold solution of sulfuryl chloride (4.6 ml, 7.728 g, 57.2 mmol) in 30 ml anhydrous DCM.

After complete addition, the suspension was warmed to room temperature and the volatiles were removed in vacuo. The residue was dried in oil-pump vacuo for 15 min, then it was extracted with hexane (150 ml). The hexane suspension was filtered and the hexane was removed in vacuo to give the crude product as dark purple oil which was used for the next step without further purification. There is still some unreacted cyclopropylbromide present.

Crude yield: 1.1 g (38%).

Step B: N-(3.4-difluoro-2-(2-fluoro-4-iodophenvlamino)-6-methoxyphenyl) cyclobutanesulfonamide

According to the general procedure B, the cyclobutylsulfonyl chloride prepared in the step above was reacted with 5,6-difluoro-Nl-(2-fluoro-4-iodophenyl)-3-methoxy-benzene1,2-diamine to obtain the title product. Yield: 75%. 'H-NMR (300 MHz, CDCI3): δ = 7.44 (s,

1H, br), 7.41-7.36 (dd, 1H), 7.24-7.23 (m, 1H), 6.54-6.38 (m, 2H), 5.90 (s, 1H, br), 3.85-3.75 (m, 5H), 2.60-2.40 (m, 2H), 2.25-2.15 (m, 1H), 2.15-1.95 (m, 2H); mtz= 511 [M-l]’.

Example 62

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylaiiaino)-6-methyIphenyl)-l-(2,325 dihydroxypropyl)cyclopropane-l-sulfonamide:

Step A: (3.4,5-Trifluorophenvl)methanol:

WO 2007/014011

PCT/US2006/028326

F

To a cooled (-5° C) solution of 3,4,5-trifluorobenzaldehyde (7.0 g, 43.75 mmol) in a mixture (50 ml, 9:1) of THF and water NaBH( (1.662 g, 43.75 mmol) was slowly added in portions over a period of 30 min. The reaction mixture was allowed to attain room temperature over a period of 2h and carefully poured into ice-cold dil HC1 (200 ml, IN). The oily layer was extracted into CH2CI2 (250 ml) and the organic layer washed with water (200 ml), dried (MgSCb) and evaporated. The crude product (7.08 g, quantitative) obtained was taken forward without further purification.

Step B: 5-(Bromomethyl)-1.2.3-trifluorobenzene:

F

To a solution of the (3,4,5-TrifluorophenyI)methanol (40 mmol) in CH2CI2 (150 ml), a solution of thionyl bromide (6.16 ml, 80 mmol) in CH2CI2 (50 ml) was added slowly. The reaction mixture stirred at room temperature for 16h and poured into ice-water (200 ml). The organic layer was separated and washed with saturated NaHCO3 (2x200 ml), water (200 ml), dried (MgSO4) and evaporated to obtain the corresponding bromo compound as a pale yellow oil in quantitative yield. The crude product was carried forward for the next reaction without further purification.

Step C: l,2,3-Trifluoro-5-methylbenzene:

WO 2007/014011

PCT/US2006/028326

The above bromo compound (40 mmol) was mixed with triethylsilane (48 mmol) and the reaction mixture was treated with solid PdCl2 (4 mmol) in small portions. After a few minutes a vigorous exothermic reaction was ensued and care was taken to reflux the contents of the flask by placing a reflux condenser. The reaction mixture was stirred at room temperature for additional 6h and the contents were allowed to settle over 16h. Then the crude liquid product was decanted carefully and carried forward for the next reaction without further purification. It was assumed tat the reaction proceeds in quantitative yield.

Step D: l,2,3-Trifluoro-5-methyl-4-nitrobenzene:

NO

Η· l,2,3-Trifluoro-5-methylbenzene (40 mmol) was added to cone. H2SO4 (50 ml) at 0-5° C. Then the reaction mixture was slowly treated with cone. HNO3 (3.39 ml, 48.44 mmol,

90%) while maintaining the internal temperature below 20° C. The reaction mixture was stirred at room temperature for 16h and poured onto ice (300 g) and the oily layer was extracted with CH2CI2 (2x125 ml). The organic layer was washed with water (2x200 ml), brine (200 ml) and dried (MgSO4) and evaporated to obtain the crude product which was purified over flash silica gel chromatography to obtain the title product (6.5 g, 85%). ]H

NMR (300 MHz, CDC13): δ 6.96 (septet, 1H), 2.39 (s, 3H). 19FNMR (CDC13): δ -128.18, 141.50,-159.05.

Step E: 2.3 -Difluoro-N-f2-fluoro-4-iodophenyl')-5 -methvl-6-nitroaniline:

H;

WO 2007/014011

PCT/US2006/028326

2-Fluoro-4-iodoaniline and l,2,3-trifluoro-5-methyl-4-nitrobenzene were reacted using the condition described in Example 1 (Step A) to form the title compound. M-H4: 407.9

Step F: 5,6-Difluoro-Nl-(2-fluoro-4-iodophenyD-3-methylbenzene-I.2-diamine:

2,3-Difluoro-N-(2-fluoro-4-iodophenyl)-5-methyl-6-nitroaniline was reduced using 10 the condition described in Example 1 (step B) to form the title compound. M-H4: 377.4

Step G: l-Allyl-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6methylphenyDcyclopropane-1 -sulfonamide:

According to the general procedure B, 1-ally,-cyclopropanesulfonyl chloride (142 mg, 142 mg) was reacted with 5,6-difluoro-Nl-(2-fluoro-4-iodophenyI)-3-methylbenzene-l,2diamine (150 mg, 0.4 mmole) to obtain the title product (100 mg, 47%); m/z = 521 [M-l]‘.

Step H: N-(3.4-difluoro-2-(2-fluoro-4-iodophenylamino,)-6-methvlphenvl')-l-f2,3dihydroxypropyllcyclopropane-l-sulfonamide:

WO 2007/014011

PCT/US2006/028326

HO

JO?,

F l-Allyl-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methylphenyl) cyclopropane-l-sulfonamide (150 mg, 0.29 mmole) and 4-methylmorpholine N-oxide (33 mg, 0.29 mmole) was dissolved in THF (5 mL). Osmium tetroxide was added at room temperature (0.029 mmole, 0.18 mL, 4% in H2O) and the reaction mixture was stirred at room temperature for 16 hours. EtOAc was added, the organic phase was washed with water, dried (MgSOzt) and concentrated under reduced pressure. The residue was purified over silica gel chromatography (eluants: EtOAc/ MeOH) to obtain the titled product (0.110 g, 68 %). 'H NMR (300 MHz, CDC13): δ 7.07 (m, 1H), 6.97 (br m, 2H), 6.84 (m, 2H), 6.60 (br m, 2H),

3.98 (br m, 1H), 3.58 (m, 1H), 3.43 (m, 1H), 3.20 (d, J= 3.9 Hz, 1H), 2.42 (s, 3H), 2.31 (dd, J= 9.9 Sc 15.6 Hz, 1H),2.O1 (brt, 1H), 2.31 (dd, J= 9.9 & 15.6 Hz, 1H), 1.66 (dd, 7=2.1 & 15.9 Hz, 1H), 1.52 (m, 1H), 1.40 (m, 1H), 0.91 (m, 2H).

Example 63

1-(2,3-Dihydroxypropyl)-N-(6-ethyl-3,4-difluoro-2-(2-fluoro-4-iodophenyIamino) phenyl) cyclopropane-l-sulfonamide:

Step A: 1 -(3,4,5-Trifluorophenvl)ethanol:

HO'

F

An ethereal solution (17.41 ml, 52.24 mmol, 3M) of MeMgBr was slowly added at 78° C to a solution of 3,4,5-trifluorobenzaldehyde (6.96 g, 43.53 mmol) in THF (125 ml). The reaction mixture was stirred at room temperature for 16h and was cooled (0° C) and was quenched, sequentially, with excess ethyl acetate (10 ml) and water (5 ml). Excess anhydrous MgSC>4 (5 g) was added and stirred for 30 minutes at room temperature. The suspension was

WO 2007/014011

PCT/US2006/028326 filtered over celite and the solids were washed with ethyl acetate (2x25 ml). The combined filtrate was evaporated to obtain the product in quantitative yield (7.65 g).

Step B: 5-(1 -BromoethvD-l,2,3-trifluorobenzene:

To a solution ofthe 1-(3,4,5-Trifluorophenyl)ethanol: (7.65 g, 43.5 mmol) in CH2CI2 (250 ml), a solution of thionyl bromide (18.1 g, 87 mmol) in CH2CI2 (50 ml) was added slowly. The reaction mixture stirred at room temperature for 16h and poured into ice-water (200 ml). The organic layer was separated and washed with saturated NaHCOj (2x200 ml), water (200 ml), dried (MgSCL) and evaporated to obtain the corresponding bromo compound as a pale yellow oil in quantitative yield (10.4 g). The crude product was carried forward for the next reaction without further purification.

Step C: 5-Ethyl-l,2,3-trifluorobenzene:

CH;

The above bromo compound (9.65 g, 40.4 mmol) was mixed with triethylsilane (41 mmol) and the reaction mixture was treated with solid PdCk (177 mg, 4 mmol) in small portions. After a few minutes a vigorous exothermic reaction was ensued and care was taken to reflux the contents of the flask by placing a reflux condenser. The reaction mixture was stirred at room temperature for additional 6h and the contents were allowed to settle over 16h Then the crude liquid product was decanted carefully and carried forward for the next reaction without further purification. It was assumed tat the reaction proceeds in quantitative yield.

Step D: l-Ethyl-3.4,5-trifluoro-2-nitrobenzene:

WO 2007/014011

PCT/US2006/028326

CH, NO,

F

F l,2,3-Trifluoro-5-methylbenzene (6.46 g, 40.4 mmol) was added to cone. H2SO4 (50 ml) at 0-5° C. Then the reaction mixture was slowly treated with cone. HNO3 (3.39 ml, 48.44 mmol, 90%) while maintaining the internal temperature below 20° C. The reaction mixture was stirred at room temperature for 16h and poured onto ice (300 g) and the oily layer was extracted with CH2CI2 (2x125 ml). The organic layer was washed with water (2x200 ml), brine (200 ml) and dried (MgSO^) and evaporated to obtain the crude product which was purified over flash silica gel chromatography to obtain the title product (6.6 g, 79%). ‘H NMR (CDCb): δ 6.98 (septet, 1H), 2.68 (q, 2H), 1.26 (t, J= 7.8 & 7.2 Hz, 3H).

Step E: 3-Ethvl-5.6-difluoro-N-(2-fluoro-4-iodophenyl)-2 nitroaniline:

2-Fluoro-4-iodoaniline (2.05 g, 10 mmole) and 1-ethyl-3,4,5-trifluoro-2-nitrobenzene (2.37 g, 10 mmole) were reacted using the condition described in example 1 (Step A) to form the title compound (2.47 g, 60%); m/z = 407 [M-l]'.

Step F: 3 -Ethyl-5,6-difluoro-N 1 -(2-fluoro-4-iodophenyl)benzene-1,2-diamine:

WO 2007/014011

PCT/US2006/028326 l,2,3-Trifluoro-5-methyl-4-nitrobenzene (2.47 g, 5.85 mmole) was reduced using the condition described in example 1 (Step B) to form the title compound. M-H+: 393

Step G: 1 -Allvl-N-( 6-ethyl-3,4-difluoro-2-(2-fluoro-45 iodophenylamino)phenyl)cyclopropane-l-sulfonamide:

According to the general procedure B, 1-allyl-cyclopropanesulfonyl chloride (230 mg, 10 1.27 mmole) was reacted with 5,6-difluoro-Nl-(2-fluoro-4-iodophenyl)-3-methylbenzene1,2-diamine (100 mg, 0.255 mmole) to obtain the title product (72 mg, 53%); m/z = 535 [Mi]·.

Step H: l-f2,3-Dihvdroxvpropyl)-N-f6-ethvl-3,4-difluoro-2-(2-fluoro-415 iodophenylaiTiino)phenvDcyclopropane-l-sulfonamide:

l-AIIyl-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methylphenyl) cyclopropane-l-sulfonamide (70 mg, 0.13 mmole) and 4-methylmorpholine N-oxide (15 mg,

0.13 mmole) was dissolved in THF (2 mL). Osmium tetroxide was added at room temperature (0.013 mmole, 0.075 mL, 4% in H2O) and the reaction mixture was stirred at room temperature for 16 hours. EtOAc was added, the organic phase was washed with water, dried (MgSOA and concentrated under reduced pressure. The residue was purified over silica

WO 2007/014011

PCT/US2006/028326 gel chromatography (eluants: EtOAc/ MeOH) to obtain the titled product. ’H NMR (300

MHz, CDCb): δ 7.38 (dd, 7= 2.1 & 10.8 Hz, 1H), 7.27 (m, 2H), 7.12 (br s, 1H), 6.91 (dd, 7=

8.1 & 10.8 Hz, 1H), 6.69 (br s, 1H), 6.36 (dt, 7= 4.8, 8.7 & 13.5 Hz, 1H), 4.00 (m, 1H), 3.62 (dd, 7= 3.6 & 10.5 Hz, 1H), 3.47 (br m, 2H), 2.81 (q, 2H), 2.40 (dd, 7= 10.2 & 15.9 Hz, 1H),

1.73 (br m, 2H), 1.58 (m, 1H), 1.43 (m, 1H), 0.94 (m, 2H).

Example 64

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-(2-methoxyethoxy)phenyI)-l-(2,3dihydroxypropyl)cyclopropane-l-sulfonamide:

Step A: 1.2,3 -Trifluoro-5-(2-methoxyethoxv)-4-nitrobenzene:

To a mixture of 3,4,5-trifluoro-2-nitrophenol (1.93, 10 mmol), Ph3P (3.93 g, 15 mmol), and 2-methoxy-ethanol (1.18 ml, 15 mmol) in anhydrous THF (25 ml) a solution of diisopropyl azodicarboxylate (2.91 ml, 15 mmol) in THF (5 ml) was added at 0° C and the reaction mixture was stirred at room temperature for 16h. The volatiles were evaporated and the residue was dissolved in CH2CI2 (100 ml) and the organic layer was washed with water (100 ml), brine (100 ml) dried (MgSCU) and evaporated. The residue obtained was purified over flash silica gel chromatography to obtain the titled product in 68% (1.70 g) yield. ’H NMR (300 MHz, CDCb): δ 6.78 (ddd, 7= 2.4, 6.0, 11.7 Hz, 1H), 4.19 (t, 7= 4.5 Hz, 2H), 3.72 (t, 7= 4.5 Hz, 2H), 3.39 (s, 3H).

Step B: 2,3-Difluoro-N-(2-fluoro-4-iodophenyl)-5-(2-methoxvethoxy)-6-nitroanilme:

WO 2007/014011

PCT/US2006/028326

2-Fluoro-4-iodoaniIine (1.6 g, 6.8 mmole) and l,2,3-trifluoro-5-(2-methoxyethoxy)-4nitrobenzene (1.7 g, 6.8 mmole) were reacted using the condition described in Example 1 (Step A) to form the title compound (1.02 g, 32 %); m/z = 467 [M-1]'.

Step C: 5,6-Difluoro-Nl-(2-fluoro-4-iodophenvl)-3-f2-methoxyethoxy)benzene-l,2diamine:

2,3-Difluoro-N-(2-fluoro-4-iodophenyl)-5-(2-methoxyethoxy)-6-nitroaniline (1.017 g,

2.17 mmole) was reduced using the condition described in Example 1 (Step B) to form the title compound; m/z = 337 [M-1].

Step D: l-Allvl-N-f3,4-difluoro-2-(2-fluoro-4-iodophenvlamino)-6-(215 methoxyethoxy)phenvl)cyclopropane-l-sulfonamide:

According to the general procedure B, 1-allyl-cyclopropanesulfonyl chloride (450 mg, 20 2.5 mmole) was reacted with 5,6-difluoro-Nl-(2-fluoro-4-iodophenyl)-3-(2methoxyethoxy)benzene-l,2-diamine (219 mg, 2.5 mmole) to obtain the title product (230 mg, 78%); m/z = 581 [M-1]'..

Step E: N-f3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-(225 meth0xyethoxv)phenvl)-l-(2,3-dihvdroxypropvDcvclopropane-l-sulfonamide:

WO 2007/014011

PCT/US2006/028326

l-allyl-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-(2-methoxyethoxy) phenyl) cyclopropane-l-sulfonamide ( 230 mg, 0.395 mmole) and 4-methylmorpholine N-oxide (46 mg, 0.395 mmole) was dissolved in THF (2 mL). Osmium tetroxide was added at room temperature (0.039 mmole, 0.25 mL, 4% in H2O) and the reaction mixture was stirred at room temperature for 16 hours. EtOAc was added, the organic phase was washed with water, dried (MgSO^ and concentrated under reduced pressure. The residue was purified over silica gel chromatography (eluants: EtOAc/ MeOH) to obtain the titled product. ]H NMR (300 MHz, CDC13): δ 7.36 (dd, /= 1.8 & 10.5 Hz, 1H), 7.27 (m, 2H), 6.56 (dd, /= 6.9 & 11.4 Hz, 1H), 6.40 (dt, /= 5.7, 7.5 & 12.9 Hz, 1H), 4.17 (m, 2H), 4.01 (m, 1H), 3.78 (m, 2H), 3.60 (dd, /= 3.6 & 11.1 Hz, 1H), 3.47 (m, 1H), 3.45 (s, 3H), 2.36 (dd, /= 9.6 & 15.9 Hz, 1H),

1.78 (dd, /= 2.4 & 15.6 Hz, 1H), 1.45-1.25 (m, 2H), 0.89 (m, 2H).

Example 65

2,4~dichloro-N-(3,4-difluoro-2-(2-fluoro-4-iodophenyIamino)phenyI) benzene sulfonamide:

Synthesized by method A using the appropriate sulfonyl chloride, m/z = 571 [M-l]'.

Example 66

2-chloro-N-(3,4-difluoro-2-(2-fluoro-4-iodophenyIamino)pheny])-4-(trifluoromethyl) benzenesulfonamide:

100

WO 2007/014011

PCT/US2006/028326

Synthesized by method A using the appropriate sulfonyl chloride. m/z = 605 [M-l]'.

Example 67

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-2-(trifluoromethoxy) benzene sulfonamide:

Synthesized by method A using the appropriate sulfonyl chloride, m/z = 587 [M-l]'.

Example 68

4-(N-(3,4-diflnoro-2-(2-fluoro-4-iodophenylamino)phenyI)sulfamoyI)benzoic acid:

Synthesized by method A using the appropriate sulfonyl chloride, m/z = 584 [M-l]'.

101

WO 2007/014011

PCT/US2006/028326

Example 69

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyI)benzenesulfonamide:

Synthesized by method A using the appropriate sulfonyl chloride, m!z = 503 [M-l]'.

Example 70

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyI)-2-fluorobenzene sulfonamide:

Synthesized by method A using the appropriate sulfonyl chloride. m!z = 521 [M-l]'.

General procedure D: substitution of the iodine atom:

A suspension containing 1 eqv. aryl iodide, 1.5 equiv. of the boronic acid or boronic ester, 0.25 eqv. PdCl2(dppf) x DCM andlO eqv. anhydrous K2CO3 powder in a deoxygenated mixture of dioxane and water (3:1) was heated in a microwave reactor for 60 min at 115 °C. It was extracted using aq. NH4CI / THF, and the organic fraction was dried using Na2SO4.

The crude reaction products were purified using flash-column chromatography (Si, EtAc / Hexanes, or CHCI3 / MeOH). Yields: 20-40%.

Example 71

N-(3,4-difluoro-2-(2-fluoro-4-methylphenyIamino)phenyl)cyclopropanesulfonamide;

102

WO 2007/014011

PCT/US2006/028326

General procedure D : ’H-NMR (500 MHz, CDC13): δ = 7.38-7,36 (m, IH), 7.06-7.03 (q, 1H), 6.92-6.90 (1H), 6.73-6.72 (d, 1H), 6.63 (s, 1H, br), 6.37-6.33 (t, 1H), 5.54 (s, 1H, br),

2.42-2.39 (m, 1H), 2.25 (s, 3H), 1.14-1.11 (m, 2H), 0.94-0.90 (m, 2H); m!z = 355 [M-l]’.

Where racemic mixtures of chiral compounds have been resolved into separate enantiomers, the phrase “substantially free” of the epimer, as used herein, means an enantiomeric excess of at least 90%.

103

WO 2007/014011

PCT/US2006/028326

Biological activity

Generation of IC50 Data

Materials and preparation of reagents: Human GST-MEK1 and the constitutively active allele GST-MEK1CA (harboring the mutations Ser218Asp and Ser222Asp) were subcloned into the yeast expression vector pGEM4Z (Promega, Madison, WI) from the wild type human MEK1 cDNA. GST-MEK1CA was expressed in Escherichia coli and partially purified using Glutathione Sepharose 4B affinity resin (Amersham Pharmacia Biotech, Piscataway, NJ). The ERK2 allele was subcloned from MAPK2/Erk2 cDNA (wild type) in pUSEamp (Upstate Biotechnology, Inc., Waltham, MA) into the vector pET21a (Novagen,

Madison, WI) resulting in an N-terminal histidine-tagged mouse ERK2 allele. ERK2 was expressed and purified to homogeneity [Zhang, 1993 #33]. Myelin basic protein (MBP) was purchased from Gibco BRL (Rockville, MD). EasyTides adenosine 5'-triphosphate (ATP) ([γ-33Ρ]) (NEN Perkin Elmer, Wellesley, MA) was the source of radiolabel for all kinase reactions. Activated Raf-1 (truncated) and activated MAPKinase 2/ERK2 were purchased from Upstate, Inc. (Lake Placid, NY). 4-20% Criterion Precast gels were purchased from Bio-Rad (Hercules, CA).

Determination of enzymatic activity: Compounds were diluted from dimethylsulfoxide (DMSO) stocks into lxHMNDE (20 mM HEPES pH 7.2,1 mM MgCh,

100 mM NaCl, 1.25 mM DTT, 0.2 mM EDTA). A typical 25-microliter assay contained

0.002 nanomoles MEK1CA, 0.02 nanomoles ERK2,0.25 nanomoles MBP, 0.25 nanomoles unlabeled ATP, and 0.1 pCi [γ33Ρ] ATP. The screening assay essentially comprised four additions. Five pi of diluted compound were dispensed to 96-well assay plates. Ten pi of 2.5x enzyme cocktail (MEK1CA and ERK2 only) were then added to each well followed by a pre25 incubation for 30 minutes at ambient temperature. Ten pi of 2.5x substrate cocktail (labeled and unlabeled ATP plus MBP) were then added, followed by incubation for 60 minutes at ambient temperature. Finally, 100 pi of 10% trichloroacetic acid (TCA) were added and incubated for 30 minutes at room temperature to halt the reaction and precipitate radiolabeled protein products. Reaction products were harvested on glass fiber 96 well filter plates prewetted with water and 1 % pyrophosphate. The filter plate was then washed 5 times with water. Water was displaced by absolute ethanol and the plate was allowed to air dry for 30 minutes at room temperature. A back seal was applied manually and 40 pi of scintillation

104

WO 2007/014011

PCT/US2006/028326 cocktail were dispensed to each well. A top seal was applied and the plate was counted in the TopCount for two seconds per well.

For certain experiments a truncated version of MEK. that requires activation by Raf kinase were used.

Generation of EC5Q Data

Effects of compounds in the cell were determined by Western blotting for phosphorylated ERK. MDA-MB-231 breast cancer cells were plated in a 48 well plate at 20,000 cells per well and grown in a 37° humidified CO2 incubator. The following day, the growth media (DMEM + 10% fetal bovine serum) was removed and replaced with starve media (DMEM + 0.1% fetal bovine serum). Cells were incubated in the starve media for sixteen hours and then treated with a range of compound concentrations for thirty minutes. After incubation with compound, cells were stimulated with lOOng/ml EGF for five minutes. The cells were then lysed and analyzed by Western blot using a monoclonal antibody raised to phosphorylated ERK. The signal was amplified using a secondary antibody conjugated to a near -IR dye and detected on a Licor Odyssey scanner. The intensity of signal was quantitated and this data was used to generate dose response curves and EC50 calculations.

Legend: A, EC50 = < 2.0nM; B, EC50 - 2.0-15nM; C, EC50 = 15nM-100nM; 20 D, EC50 > lOOnM, IC50 < 20pM; F, EC50 > lOOnM, IC50 > 20pM

<td> Compound Number</td><td> Structure</td><td> ACTIVITY μΜ</td>

105

WO 2007/014011

PCT/US2006/028326

<td> Compound Number</td><td colspan="3"> Structure</td><td> ACTIVITY μΜ</td>

106

WO 2007/014011

PCT/US2006/028326

<td> Compound Number</td><td> Structure</td><td> ACTIVITY μΜ</td>

107

WO 2007/014011

PCT/US2006/028326

<td> Compound Number</td><td> Structure</td><td> ACTIVITY μΜ</td>

<td> 1018 (Racemic)</td><td> HO HO-0 //x o NH F ΧνηΛ IL. 1 F</td><td> A</td>

<td> 1019 (Racemic)</td><td> o X</td><td> A</td>

108

WO 2007/014011

PCT/US2006/028326

<td> Compound Number</td><td> Structure</td><td> ACTIVITY μΜ</td>

<td> 1020 (Racemic)</td><td> HO HO—( NH F F</td><td> A</td>

<td> 1021 (R isomer)</td><td> X o</td><td> A</td>

<td> 1022 (S isomer)</td><td> OH H0U // \ Oz NH F F</td><td> B</td>

<td> 1023 (R isomer)</td><td> HO X ZX=O 0' \ NH F XC0, F</td><td> B</td>

109

WO 2007/014011

PCT/US2006/028326

<td> Compound Number</td><td> Structure</td><td> ACTIVITY μΜ</td>

<td> 1024 (S isomer)</td><td> HO o=v° NH F 'ΰτώ, F</td><td> B</td>

110

WO 2007/014011

PCT/US2006/028326

<td> Compound Number</td><td> Structure</td><td> ACTIVITY pM</td>

111

189201/2

Contents236

184 members in 38 offices

This recordMember, by publication datePriority claim28 more offices are in the list below

Priority claims16

Priority claims
Document	Office	Kind	Date
70181405	United States of America	P	2005-07-21
70181405	United States of America	P	2005-07-21
70671905	United States of America	P	2005-08-08
70671905	United States of America	P	2005-08-08
73163305	United States of America	P	2005-10-28
73163305	United States of America	P	2005-10-28
2006028326	United States of America	W	2006-07-21
2006028326	United States of America	W	2006-07-21
60701814	–	–	–
60706719	–	–	–
60731633	–	–	–
PCTUS2006028326	–	–	–
US20050701814P	–	–	–
US20050706719P	–	–	–
US20050731633P	–	–	–
WO2006US28326	–	–	–

Members184

Family members, oldest first
Document	Office	Kind
AU2006272837A1	Australia	A1	2007-02-01
CA2618218A1	Canada	A1	2007-02-01
WO2007014011A2	World Intellectual Property Organization (WIPO)	A2	2007-02-01
US2007244164A1	United States of America	A1	2007-10-18
AU2007237901A1	Australia	A1	2007-10-25
CA2649122A1	Canada	A1	2007-10-25
WO2007121481A2	World Intellectual Property Organization (WIPO)	A2	2007-10-25
US2008058340A1	United States of America	A1	2008-03-06
MX2008002114A	Mexico	A	2008-04-17
EP1912636A2	European Patent Office (EPO)	A2	2008-04-23
WO2007121481A3	World Intellectual Property Organization (WIPO)	A3	2008-05-22
KR20080068637A	Republic of Korea	A	2008-07-23
AU2008206045A1	Australia	A1	2008-07-24
CA2675358A1	Canada	A1	2008-07-24
WO2008089459A1	World Intellectual Property Organization (WIPO)	A1	2008-07-24
US2008255133A1	United States of America	A1	2008-10-16
WO2007121481A8	World Intellectual Property Organization (WIPO)	A8	2008-10-16
MX2008013097A	Mexico	A	2008-10-27
KR20090005193A	Republic of Korea	A	2009-01-12
EP2012786A2	European Patent Office (EPO)	A2	2009-01-14
AU2008282338A1	Australia	A1	2009-02-05
CA2693390A1	Canada	A1	2009-02-05
CA2694646A1	Canada	A1	2009-02-05
CA2924418A1	Canada	A1	2009-02-05
CA2924436A1	Canada	A1	2009-02-05
WO2009018233A1	World Intellectual Property Organization (WIPO)	A1	2009-02-05
WO2009018238A1	World Intellectual Property Organization (WIPO)	A1	2009-02-05
IL189201A0	Israel	A0	2009-02-11
US2009082457A1	United States of America	A1	2009-03-26
WO2007014011A3	World Intellectual Property Organization (WIPO)	A3	2009-04-23
EA200870446A1	Eurasian Patent Organization (EAPO)	A1	2009-04-28
CN101454004A	China	A	2009-06-10
CN101495118A	China	A	2009-07-29
ZA200801443B	South Africa	B	2009-08-26
US2009227681A1	United States of America	A1	2009-09-10
JP2009534408A	Japan	A	2009-09-24
AU2009236325A1	Australia	A1	2009-10-22
CA2720671A1	Canada	A1	2009-10-22
WO2009129246A2	World Intellectual Property Organization (WIPO)	A2	2009-10-22
KR20090111847A	Republic of Korea	A	2009-10-27
HK1128617A	Hong Kong, China	A	2009-11-06
HK1128617A1	Hong Kong, China	A1	2009-11-06
CR10939A	Costa Rica	A	2009-11-13
EP1912636A4	European Patent Office (EPO)	A4	2009-11-18
EP2121620A1	European Patent Office (EPO)	A1	2009-11-25
ECSP099525A	Ecuador	A	2009-11-30
MX2009007661A	Mexico	A	2009-12-14
TW200951107A	Taiwan Province of China	A	2009-12-16
MA31183B1	Morocco	B1	2010-02-01
EP2012786A4	European Patent Office (EPO)	A4	2010-02-24
EA200900959A1	Eurasian Patent Organization (EAPO)	A1	2010-02-26
AP2010005134A0	African Regional Intellectual Property Organization (ARIPO)	A0	2010-02-28
CN101663279A	China	A	2010-03-03
IL199727A0	Israel	A0	2010-04-15
EP2175885A1	European Patent Office (EPO)	A1	2010-04-21
DOP2009000181A	Dominican Republic	A	2010-04-30
ECSP109910A	Ecuador	A	2010-04-30
HK1134436A	Hong Kong, China	A	2010-04-30
HK1134436A1	Hong Kong, China	A1	2010-04-30
SV2010003469A	El Salvador	A	2010-04-30
EP2184984A1	European Patent Office (EPO)	A1	2010-05-19
CR11244A	Costa Rica	A	2010-05-20
JP2010516698A	Japan	A	2010-05-20
US7759518B2	United States of America	B2	2010-07-20
CN101808516A	China	A	2010-08-18
KR20100092424A	Republic of Korea	A	2010-08-20
EA201000268A1	Eurasian Patent Organization (EAPO)	A1	2010-08-30
MX2010001244A	Mexico	A	2010-08-31
EP2012786B1	European Patent Office (EPO)	B1	2010-10-06
AT483463T	Austria	T	2010-10-15
ATE483463T1	Austria	T1	2010-10-15
CO6210813A2	Colombia	A2	2010-10-20
US7820664B2	United States of America	B2	2010-10-26
DOP2010000045A	Dominican Republic	A	2010-10-31
MX2010011314A	Mexico	A	2010-11-12
DE602007009663D1	Germany	D1	2010-11-18
JP2010535232A	Japan	A	2010-11-18
JP2010535233A	Japan	A	2010-11-18
ECSP10010548A	Ecuador	A	2010-11-30
EP2175885A4	European Patent Office (EPO)	A4	2010-12-01
MA31881B1	Morocco	B1	2010-12-01
IL208284A0	Israel	A0	2010-12-30
US2010331334A1	United States of America	A1	2010-12-30
TN2009000291A1	Tunisia	A1	2010-12-31
KR20110014149A	Republic of Korea	A	2011-02-10
US2011033539A1	United States of America	A1	2011-02-10
US7897624B2	United States of America	B2	2011-03-01
EP2291350A2	European Patent Office (EPO)	A2	2011-03-09
ES2354182T3	Spain	T3	2011-03-10
US2011060049A1	United States of America	A1	2011-03-10
WO2009129246A3	World Intellectual Property Organization (WIPO)	A3	2011-03-31
MA32226B1	Morocco	B1	2011-04-01
US2011112152A1	United States of America	A1	2011-05-12
CR11731A	Costa Rica	A	2011-06-08
EA201001639A1	Eurasian Patent Organization (EAPO)	A1	2011-06-30
JP2011518786A	Japan	A	2011-06-30
CN102131771A	China	A	2011-07-20
HK1147396A	Hong Kong, China	A	2011-08-12
HK1147396A1	Hong Kong, China	A1	2011-08-12
BRPI0710817A2	Brazil	A2	2011-08-23

Showing 100 of 184

4 legal events, as the office reported them to INPADOC

Over the term

Point at a mark for the event

Events

Legal events, newest first
	Event	Code
2021-02-28	Patent not in force due to non-payment of renewal feesMM9K	MM9K
2016-08-31	Patent renewedKB	KB
2014-09-30	Patent grantedGrantedFF	FF
2014-09-30	Patent renewedKB	KB